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ABSTRACT 
 
Breast cancer is a major concern worldwide as it accounts for one of the highest causes of 
death. Oestrogen which is widely known for its growth-promoting function in mammary 
gland has been linked to breast cancer pathogenesis. Oestrogen exerts its effect upon binding 
to oestrogen receptors mainly ERα. The presence of ERα in breast cancer has become a 
prognostic and predictive marker in response to endocrine therapy. Transcription factors are 
proteins that regulate gene expressions by interacting with specific DNA sequences. AP-2γ, 
which is implicated in the initiation and progression of breast cancer via ErbB2 and ERα, is a 
member of AP-2 transcription factors. Forkhead box M1 (FOXM1) belongs to the family of 
Forkhead box transcription factor. High levels of FOXM1 expression are associated with the 
development and progression of breast cancer. In this study, the relationship between AP-2γ 
and FOXM1 were explored. The results suggest a direct association of AP-2γ and FOXM1 in 
MCF-7 cells and in MCF-7 derived anti-oestrogen resistant cell line, MLET2. Taken 
together, this work does not only identify the role of AP-2γ in endocrine sensitive cell line, it 
also reveals that AP-2γ might play a role in endocrine resistance. However, it also shows that 
AP-2γ may not be the key regulator of FOXM1 in breast cancer where other factors may have 
a greater influence on FOXM1. Endocrine resistance in breast cancer is a hurdle in hormonal 
therapy. Oestrogen receptor (ERα) which plays a pivotal role in breast cancer progression, 
contributes to the development of endocrine resistance. Forkhead transcription factors are 
also known to be involved in the development and progression of breast cancer. This work 
also identifies the role of FOXA1, FOXM1, FOXC2 and ERα in endocrine sensitive and 
resistant cell lines. Taken together, the results show that FOXA1 may not be a key regulator 
of FOXM1 in MCF-7 cells. However, over-expression of FOXA1 in MDA-MB-231 cell line 
led to slight reduction in FOXM1 and FOXC2 at translational levels suggesting that FOXA1 
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may play an important role in regulating those transcription factors. When the cell lines were 
treated with anti-oestrogen, tamoxifen and ICI, high levels of FOXM1 and FOXC2 were 
detected in most endocrine resistant cells compared to MCF-7 cells suggesting potential 
mediators for endocrine resistance. However, high levels of FOXA1 were observed in ERα-
expressing cell lines which are associated with better prognosis. In addition to ERα, AP-2γ 
and Forkhead transcription factors may be potential therapeutic targets for breast cancer. 
However, more studies should be conducted to validate the current findings. 
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1.1 Cancer 
 
Cancer is a diverse class of diseases that has claimed many innocent lives around the world. 
In 2002, 10.9 million cases were detected with an estimate of 6.7 million deaths globally. The 
numbers of diagnoses were expected to increase to 20 million over the next 25 years (Abbott, 
Forrest et al. 2006). There are more than 200 distinct types of cancer where breast cancer, 
lung cancer, colorectal (large bowel) cancer and prostate cancer account for over half (54%) 
of the cancers that have been identified in humans (Cancer Research, UK, 2006).  
 
Cancer is a complex evolutionary system which entails a group of heterogeneous populations 
of cells that are competing for scarce resources (Abbott, Forrest et al. 2006). Growing 
evidence suggests that tumorigenesis involves a multistep process and these processes reflect 
genetic modification which drives the transformation of normal cells to tumour cells 
(Hanahan and Weinberg 2000). It is believed that cancer arises from the accumulation of 
genetic mutations where mutation in three classes of genes; oncogenes, tumour-suppressor 
genes and stability genes are known to be responsible for tumorigensis. Proto-oncogenes 
(unmutated oncogenes) stimulate normal cell division and growth in an ordered manner while 
tumor suppressor genes maintain cell growth. Stability genes are responsible for repairing 
mistakes in DNA replication during cell division (Ruccione 1999). Oncogenes and tumour-
suppressor genes drive tumorigenesis by increasing tumour cell number through activation of 
genes that are involved in cell cycle or by hampering normal apoptotic processes. Genetic 
modifications are controlled to a minimum level by stability genes; hence when these genes 
are faulty, other mutations occur at a higher rate (Lengauer, Kinzler et al. 1998; Vogelstein 
and Kinzler 2004). Six phenotypic alterations at cellular level had been proposed as 
hallmarks of cancer which includes unlimited cell division (mitosis), insensitivity to anti-
growth signals, evasion of programmed cell death (apoptosis), infinite cell replication 
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potential, continuous growth of new blood vessels (angiogenesis) and tissue invasion and 
metastasis (Hanahan and Weinberg 2000).  
 
 
 
                  
 
 
 
Figure 1.1: Hallmarks of cancer (Hanahan and Weinberg 2000) 
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1.2 Breast Cancer  
 
Breast cancer is one of the leading causes of death in women. Each year, the global incidence 
of breast cancer affects 1.2 million women. Around one in nine women in the United States 
and United Kingdom will develop cancer at some stages of their lives (Ali and Coombes 
2002; Fucito, Lucchetti et al. 2008). However, the death rate in breast cancer has been 
declining in most Western countries in the last decade due to increase in awareness that lead 
to implementation of screening programmes and more effective treatments (Guarneri and 
Conte 2004). 
Almost 90% of breast cancers occur sporadically while the remaining 10% of the cases are 
plausibly through genetic mutations (Deng 2006). Several risk factors are known to 
contribute to the development of breast cancer in women. Breast cancer is a classical 
hormone-dependent tumour and the steroid hormone oestrogen is known to contribute to the 
development and progression
 
of the disease (Massarweh and Schiff 2006). Prolonged 
exposure to oestrogen increases the risk of breast cancer, which includes late first full-term 
developing breast cancer in a woman giving birth to her first child after the age of 35 is 
threefold than a woman giving birth before the age of 20. Permanent differentiation of 
mammary stem cells may be a protective effect in early full-term pregnancy that can reduce 
lifetime risk of breast cancer. Early menarche increases the risk of breast cancer by 1.5-2.0 
fold compared to late menarche while early menopause, removal of both ovaries before the 
age of 35 decreases the risk of breast cancer about 0.6 fold compared to natural menopause. 
The association of reproductive factors in early menarche and late menopause provides 
support for a hormonal role in aetiology of the disease (Willett 1989). Alternatively, oral 
contraceptives and oestrogen-replacement therapy have also been linked to breast cancer risk. 
Besides that, environmental or dietary agents that mimic oestrogen can also increase the risk 
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of developing breast cancer, although their role in breast cancer is yet to be proven (Ali and 
Coombes 2002). Various treatments such as surgery, chemotherapy, endocrine therapy and 
others are widely used to treat breast cancer patients. However, continuous research is taking 
place to seek new avenue for treating breast cancer as the occurrence of endocrine resistance 
has been a major setback of the current treatments.  
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Figure 1.2: Incidence of 20 most common cancers excluding non-melanoma skin cancer 
diagnosed in male and female in the UK in 2006  
(Cancer Research UK, 2006) 
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1.3 Oestrogen  
 
The ovarian hormone oestrogen (the most abundant circulating form of oestrogen is 17β-
oestradiol or E2) synthesized by testosterone aromatization, plays a major role in regulating 
the changes that occur in women during puberty, including breast growth. Oestrogen 
synthesis ceases in post-menopausal women and the production of oestrogen by non-ovarian 
sources such as adipose tissue, osteoblasts and chondrocytes in the bone contributes to breast 
cancer progression (Ali and Coombes 2002; Goodsell 2002; Marino, Galluzzo et al. 2006). 
Cells grow and differentiate normally with controlled oestrogen stimulation and this contrasts 
distinctly in oestrogen-dependent breast cancer cells where the cell proliferation is 
unimpeded (Zajchowski, Sager et al. 1993). 
 
1.4 Oestrogen Receptors 
 
Oestrogen receptors (ER) namely ERα and ERβ are transcription factors which bind to their 
respective ligands to regulate transcription of target genes. Most biological effects of 
oestrogen on normal cellular processes and tumour growth are mediated by oestrogen 
receptors. These receptors belong to a large superfamily of nuclear hormone receptors and 
they are similar in terms of structure and activity (Sommer and Fuqua 2001; Schiff, 
Massarweh et al. 2003). ERα and ERβ are encoded by different genes, which are located on 
human chromosome 6 and 14, respectively (Marino, Galluzzo et al. 2006) The human ER 
subtypes comprise of six functional domains, designated A/B through F. The A/B domain, 
which is located at the N-terminal, is involved in ligand-independent transcriptional activity 
of ER while C domain is the DNA-binding domain. Through C domain, ER dimerizes and 
binds to the specific oestrogen response
 
elements (ERE) on DNA target genes. The D domain 
is a flexible hinge region between C and E domains which contains nuclear localization 
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signals. The ligand-binding domain (E/F domain), which is located at the C-terminal, is 
involved in ligand-dependent transcriptional activity of ER (Zilli, Grassadonia et al. 2009). 
ERα and ERβ are highly homologous in their DNA-binding domain (95%) and ligand-
binding domain (58%) (Marino, Galluzzo et al. 2006) ER‟s mediate positive regulation of 
gene expression with its two different domains, activating function-1 (AF-1) and activating 
function-2 (AF-2). AF-1 is hormone-independent and its function is regulated by 
phosphorylation while AF-2 is hormone-dependent and is activated upon ligand binding. 
(Normanno, Di Maio et al. 2005). Both these activating domains can work together or 
independently depending on the cell and promoter context (Atanaskova, Keshamouni et al. 
2002).  
 
In general, ERα is important in regulating female development and reproductive functions. 
ERα-knockout mice were presented with growth retardation of mammary ducts which shows 
the importance of ERα in ductal growth (Zilli, Grassadonia et al. 2009). High levels of ERα 
are known to be associated with specific cancer sub-types and to influence the patient‟s 
survival rate (Parisi, Sonderegger et al. 2009). ERα expression in breast cancer patients is 
vital in determining the response to endocrine therapy (Woodfield, Horan et al. 2007) as it  
plays a major role in breast cancer pathogenesis compared to ERβ (Schiff, Massarweh et al. 
2003). Sixty percent of primary breast cancer patients are ER-positive. Two-thirds of 
advanced ER-positive breast cancer patients respond to endocrine therapy such as tamoxifen 
(Giacinti, Claudio et al. 2006). 
 
ERβ is a relatively newly identified ER (Badve and Nakshatri 2009). ERβ is expressed in 
many tissues such as the central nervous system, the cardiovascular system, the immune 
system, the urogenital tract, the gastrointestinal tract, the kidneys and the lungs (Gustafsson 
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1999). Breast epithelial cells express 60% to 70% of ERβ at all stages of breast development 
while, ERα is only expressed at certain stages of the mammary gland development 
(Rousseau, Nichol et al. 2004). The exact role of ERβ in breast cancer remains a question due 
to poor quality reagents and the existence of at least five isoforms of ERβ (Badve and 
Nakshatri 2009). Some studies show ERβ is associated with less aggressive phenotype and 
can inhibit breast cancer cell proliferation and invasion (Rousseau, Nichol et al. 2004). It is 
evident that ERβ represses c-myc, cyclin D1 and cyclin A and activates p21 and p27 
expression leading to cell-cycle arrest at G2 phase (Zilli, Grassadonia et al. 2009). However, 
these findings differ from other groups that indicate the ratio of ERα and ERβ expression 
varies as the cancer progresses. This is evident with the increase of ERβ expression in 
patients that relapse from tamoxifen treatment exhibiting tamoxifen resistance (Rousseau, 
Nichol et al. 2004).  
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Figure 1.3: Domain structures of human oestrogen receptor α (ERα) and oestrogen 
receptor β (ERβ) 
 
Oestrogen receptor consists of six independent domains, A-F. The A/B domains are situated 
in the Activating Function-1 (AF-1) region which is hormone independent. The E/F 
domains/ligand binding domain (LBD) is in the Activating Function-2 (AF-2) region which 
requires ligand binding. The C domain is the DNA binding domain while the hinge region is 
involved in dimerization (D domain). The homology between the two receptors is represented 
in percentages (Marino, Galluzzo et al. 2006). 
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1.5 Transcriptional Co-Regulators 
 
Co-regulatory factors are among the 100 proteins that interact with ERα. These proteins are 
known as co-activators or co-repressors (Badve and Nakshatri 2009). Proteins that link the 
ERα/target promoter complex with the transcription machinery and augment the 
transcriptional activity of ERα-target genes are called co-activators. Co-activators that are 
actively involved in oestrogen signalling are the members of the p160 family of nuclear-
receptor co-activators which include nuclear-receptor co-activator 1 (NCoA1), also known as 
steroid receptor co-activator 1 (SRC-1), NCoA2 (SRC-2) and NCoA1 (SRC-3) or better 
known as amplified in breast cancer 1 (AIB1). In contrast to co-activators, proteins that 
impair the ERα/target promoter complex with the transcription machinery and inhibit the 
transcriptional activity of ERα-target genes are known as co-repressors. The co-repressors 
include nuclear-receptor co-repressor 1 (NCoR1) and NCoR2, also known as silencing 
mediator for retinoid or thyroid-hormone receptors (SMRT) (Sommer and Fuqua 2001; Zilli, 
Grassadonia et al. 2009; Romano, Adriaens et al. 2010). Recent studies have revealed the 
importance of co-regulators in determining the overall receptor activity in cancer cells (Badve 
and Nakshatri 2009). The mechanism of action of oestrogen and selective oestrogen receptor 
modulators (SERM) on certain cells and genes, mostly depend on the availability of co-
regulators. SRC-3/AIB1 is the only member of the of the p160 family of nuclear-receptor co-
activators that is significantly over-expressed in primary breast cancers and is associated with 
tamoxifen resistance. On the other hand, down-regulation of co-repressor NCoR, causes 
SERM tamoxifen, which is an ERα-antagonist to induce proliferation in breast cancer 
(Sommer and Fuqua 2001; Romano, Adriaens et al. 2010).  
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1.6 Mechanism of Action of Oestrogen Receptor 
 
The role of oestrogen receptor is effective upon binding of oestrogen which induces 
activation of the receptor (Normanno, Di Maio et al. 2005). Oestrogen that enter the cells 
binds and activates ER in the nucleus (genomic effect), resulting in its dimerization and 
phosphorylation. The oestrogen receptor complex then initiates the recruitment of specific co-
regulator proteins which are the co-activators. These co-activators augment the binding of the 
complex
  
to oestrogen response
 
elements (EREs) which is located in the promoter regions of 
oestrogen-regulated genes such as c-myc, TGF-α, progesterone receptor (PR) and others 
(Madureira, Varshochi et al. 2006; Massarweh and Schiff 2006). Subsequent
 
transcription 
leads to the synthesis of essential proteins which
 
are involved in cell growth, differentiation 
and survival. In the case of breast cancer, these proteins contribute to its progression. In 
endocrine therapy, the anti-oestrogen tamoxifen competitively binds to the ER thus altering 
the molecular conformation
 
of the receptor. This leads to the recruitment of co-repressor 
proteins and consequently, the transcriptional activation function
 
of the receptor complex is 
inhibited and gene transcription
 
is blocked (Stoica, Franke et al. 2003; Massarweh and Schiff 
2006). Besides the classical way of ER activation by oestrogen in the cell nucleus, ER 
modulates gene expression via interaction with other DNA bound-transcription factors such 
as the Fos-Jun complex at alternatively regulatory DNA sequences besides ERE such as 
Activator Protein-1 (AP-1), SP-1 (Petz, Ziegler et al. 2004; Normanno, Di Maio et al. 2005). 
 
A smaller proportion of ER are found to be in
 
the cell membrane or cytoplasm and these  are 
activated by direct interaction with a variety of signalling
 
pathways which will initiate more 
rapid cellular
 
signalling. ER action that is mediated by signalling pathways are called
 
the non-
genomic ER action (also known as membrane-initiated
 
steroid signalling or MISS) 
(Massarweh and Schiff 2006). In the non-genomic action, several polypeptide growth factors 
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such as epidermal growth factor (EGF), heregulin, insulin, insulin-like growth factor 1 (IGF-
1), and transforming growth factor-α (TGF-α), as well as dopamine, cyclic AMP and phorbol 
esters stimulates ER activation (Ali and Coombes 2002). Cell surface receptor tyrosine 
kinases (RTKs) that posses an intrinsic protein kinase activity mediates the growth factor 
activity in the cells (Stoica, Franke et al. 2003). The signal transduction pathways that 
activate ERα are mediated by phosphorylation, which can stimulate the transcriptional 
potential of ERα, often in a ligand-independent manner. Phosphorylation of ERα by RTKs 
can occur through at least two pathways, which are the extracellular-signal-regulated kinases 
(ERK) pathway and the phosphatidylinositol-3-OH kinase (PI3K) pathway (Ali and Coombes 
2002). 
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Figure 1.4: Genomic and non-genomic actions of oestrogen receptor (ER) 
 
Oestrogen Receptor (ER) is mediated through genomic and non-genomic action. In the 
genomic action, ER binds to oestrogen (E) activating transcription either via direct binding to 
oestrogen responsive elements (ERE) in targeted genes promoters (classical mode) or via 
binding to other transcription factors (Fos-Jun complex) at AP-1 region in target genes (non-
classical mode). In the non-genomic action, growth factor signalling pathways mainly MAPK 
and PI3K stimulates ER activity in the absence of E (Schiff, Massarweh et al. 2003). 
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1.6.1 Mitogen-Activated Protein (MAP) Kinase 
 
Mitogen-activated protein kinase (MAP kinase) is a key signal transducing protein, which is 
involved in regulating cell proliferation and cell death. The MAP kinase signalling pathway 
involves a series of protein-protein complexes interaction. Peptide growth factors that bind to 
cell surface tyrosine kinase receptors (RTK) initiate a kinase sequence cascade. Binding of 
the ligand triggers the Shc adaptor protein to bind to its peptide hormone receptor.  A 
phosphorylated Shc then binds to other adaptor proteins GRB-2 and SOS. This is followed by 
the activation of RAS-RAF-MEK and, finally, the ERK-1 and ERK-2, extracellular-signal-
regulated kinases (classical Mitogen Activated Protein kinases). The phosphorylation of 
ERK-1 and ERK-2 by MEK either activates or suppresses the transcription of downstream 
targets. Deregulation of the MAP kinase signalling pathway is often observed in cancer cells. 
About 30% of human cancers are presented with RAS mutations and it is apparent that this 
signalling pathway is constitutively active in various cancers (Dunn, Espino et al. 2005). It 
has been shown that breast cancer cells often express higher level of MAP kinase activity 
compared to normal cells. MAP kinase is able to phosphorylate the ER, either directly or 
indirectly that leads to an increase in its transcription efficiency. Therefore, over-expression 
of RTKs can turn the normal molecular cross-talk between ER and growth factor receptors 
into an aberrant circle responsible for cell proliferation and ER activities (Zilli, Grassadonia 
et al. 2009). In addition, increased ERK activity could also result in resistance to endocrine 
therapy which is linked to poorer response, hence leading to shorter life span (Ali and 
Coombes 2002; Santen, Song et al. 2002). 
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Figure 1.5: Activation of MAP kinase in a series of protein-protein complexes 
interaction  
 
Growth factor that binds to Receptor Tyrosine Kinase (RTK) activates it leading to binding of 
Shc, GRB-2 and Sos. This is followed by the activation of Ras-Raf-MEK and MAP Kinase 
which then regulates gene transcription (Santen, Song et al. 2002). 
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1.6.2 Phosphatidylinositol-3-Kinase (PI3K)  
 
Phosphatidylinositol kinases are one of the members of the PI3K family which consists of a 
large family of lipid and serine/threonine kinases (Hennessy, Smith et al. 2005). Upon 
activation of growth factors such as insulin, the insulin-like growth factors and members of 
the epidermal growth factor (EGF) family, PI3Ks phosphorylates phosphatidylinositol-4, 5-
bisphosphate (PIP2) to phosphatidylinositol-3, 4, 5-bisphosphate (PIP3). PIP3 then recruits 
and activates various downstream targets which include the serine-threonine protein kinase 
Akt, also known as protein kinase B (PKB). The activation of Akt promotes cell proliferation 
and anti-apoptotic responses which are characteristics of tumourigenesis. The tumour 
suppressor gene PTEN inhibits PI3K activity. Loss of PTEN function can lead to constitutive 
activation of the PI3K pathway which is a contributing factor to cancer development and 
progression (Osborne and Schiff 2003). Phosphatidylinositol-3-kinase signalling pathway is 
involved in modulating normal cellular processes such as growth and survival (Hennessy, 
Smith et al. 2005). Deregulation of the PI3K pathway components have been implicated in 
human cancer (Luo, Manning et al. 2003). Previous studies have shown that PI3K 
(phosphoinositide-3-kinase) pathway plays a vital role in ERα activity where ERα 
phosphorylation by Akt occurs at serine 167 and results in ligand–independent ERα 
activation. In breast cancer cells, the expression and activity of all three Akt family members 
are elevated. As a result, altered expression or mutation of the components of PI3K–Akt 
pathway could be a key of resistance to endocrine therapy (Ali and Coombes 2002; Luo, 
Manning et al. 2003).  
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Figure 1.6: Diagrammatic representation of PI3K/Akt pathway  
 
The PI3K/AKT pathway is another important pathway in regulating normal cellular 
processes. Binding of growth factor to Receptor Tyrosine Kinase (RTK) initiates a series of 
cascade activation leading to regulation of target genes. In this pathway phosphorylation of 
Akt leads to activation of many downstream targets that control cell cycle entry, cell survival. 
(Luo, Manning et al. 2003). 
 
 
 
 
 
 
 
 
 
 
cyclin D1 
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1.7 Cell Cycle  
 
Cell cycle is an important process for cell division and cell proliferation. It is the motor, and 
the basis for cancer cell growth and progression (Lupulescu 2001). The events of cell cycle 
occur in four distinct phases. The interphase, which is the period from the end of one nuclear 
division to the beginning of the next, consists of first gap phase (G1), S phase where DNA 
replication takes place and second gap phase (G2). The final phase in which cell division 
transpires is the M phase (mitosis) where the replicated chromosomes are segregated into two 
genetically identical daughter cells. Cells can enter the resting or quiescent phase (G0) after 
the division or also in the absence of mitogen stimulation. The complete cell cycle occurs 
within 16-24 hours depending on the species and tissue variables (Collins, Jacks et al. 1997). 
Cell cycle which takes place in an organized manner is governed by many regulatory 
mechanisms that either allow or hinder its progression (Golias, Charalabopoulos et al. 2004).  
It is regulated by accelerator molecules termed „cyclin‟ and „cyclin dependent kinase‟ (cdk) 
and brake molecules termed „cyclin dependent kinase inhibitor‟ (CKI) (Dobashi 2005). 
 
Previously, Hanahan and Weinberg, 2000 proposed unchecked cell proliferation as one of the 
six hallmarks of cancer which in turn leads to tumorigenesis. Many cell cycle regulators that 
control the ordered set of cell cycle events are found to be deregulated in cancer cells. 
Moreover, accumulation of genetic and epigenetic modifications to oncogenes and tumor 
suppressor genes contributes to the tumor development. Genes that positively control cell-
cycle checkpoints are mutated while tumor suppressor genes that negatively regulate cell 
cycle checkpoints are inactivated in cancer cells (Collins, Jacks et al. 1997)  One of the most 
important tumor suppressor genes that are in involved in the cell cycle regulation is the p53 
gene where it is found to be mutated in more than half of all human cancers (Golias, 
Charalabopoulos et al. 2004). 
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Figure 1.7: Cell cycle and its four distinct phases (Golias, Charalabopoulos et al. 2004) 
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1.8 Forkhead box (Fox) Proteins 
 
Forkhead box (Fox) proteins are a large family of evolutionary conserved transcription 
factors that can be found in species ranging from yeast to human. They are classified by a 
100-amino-acid common DNA-binding domain (DBD) termed the Forkhead box or winged 
helix domain. A standardized nomenclature for the known Forkhead members were 
developed as numerous names and classification system made it difficult to characterize the 
newly found Forkhead transcription factors (Kaestner, Knochel et al. 2000; Myatt and Lam 
2007). There are at least 41 genes currently identified in humans with the presence of 19 Fox 
gene subfamilies (Fox A–S). FOXA proteins were the first mammalian Forkhead member to 
be identified where its genes were found in Drosophila melanogaster that gave the gene 
family its name (Myatt and Lam 2007; Fu and Tindall 2008).  
 
As transcription factors, the Fox proteins play a vital role in both embryonic development and 
adult tissue homeostasis by regulating normal cellular processes such as cell
 
growth, 
proliferation, differentiation, longevity, and transformation (Teh, Wong et al. 2002). 
Although Fox proteins are involved in the normal biological processes, their regulation and 
function vary significantly between families despite the highly conserved Forkhead box 
DBD. Fox proteins regulate gene expression by activating and repressing the genes through 
the recruitment of co-regulators mainly the histone deacetylases (HDACs). Besides that, Fox 
proteins can also interact with tumour suppressor gene (p53), ER to control gene expression. 
Deregulation of Fox factors can lead to tumour initiation by causing cell resistance to stress, 
apoptosis, and increase in proliferation thus promoting survival through the repression and/or 
stimulation of gene expression. Fox proteins are found to be deregulated at two levels, 
through genetic mutation and post-translational modifications. The current research on Fox 
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proteins reveals that FOXO, FOXA, FOXM, FOXC and FOXP are associated with 
tumorigenesis and cancer progression in several types of cancer (Myatt and Lam 2007). 
 
1.8.1 FOXM 
 
The Forkhead box M1 (FOXM1) protein is being investigated extensively as it is recognized 
for its role in cell cycle regulation. FOXM1 is expressed in the G1/S phase and G2/M phase 
of cell cycle and the expression is maintained during S phase and M phase (Costa 2005; 
Petrovic, Costa et al. 2008). It is mainly found in the cytoplasm at late G1/S phase and 
FOXM1 is imported to the nucleus before entry into G2/M phase due to its phosphorylation, 
mediated by Cdk2-cyclin E and Raf-MEK-ERK (Myatt and Lam 2007). The transcriptional 
activation of FOXM1 occurs when the cyclin-dependent kinase (Cdk) and cyclin complex 
binds to its transcriptional activation domain and phosphorylation of Cdk takes place. This 
phosphorylation mediates the recruitment of transcriptional co-activator, Cyclic AMP 
response element binding protein (CREB) which enhances targeted gene regulation (Costa 
2005). There are several genes that controls cell cycle activity and these genes are the 
downstream targets of FOXM1 which includes CENP-F, Aurora B kinase, Polo-like-kinase 
(Plk1), Cdc25b phosphatase and cyclin B genes. Unlike normal cells, FOXM1 is constantly 
expressed in tumour cells (Petrovic, Costa et al. 2008). Over-expression of FOXM1 leads to 
increase in cell cycle progression and growth arrest inhibition and this has been implicated in 
development of many cancers of the breast, lung, liver, brain and prostate (Myatt and Lam 
2007). In breast cancer cells, FOXM1 was identified as a physiological regulator of ERα 
expression. FOXM1 regulation of ERα occurs at transcriptional and promoter levels through 
binding directly to Forkhead responsive elements (FHREs) on the ERα promoter (Madureira, 
Varshochi et al. 2006).  
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Figure 1.8: Role of FOXM1 transcription factor in cell cycle regulation  
 
FOXM1 regulates transcription of genes that are involved in cell-cycle. In order for FOXM1 
transcriptional activity to take place, it requires the binding of Cdk2-cyclin-E/A (G1/S phase) 
or Cdk1-cyclin-B (G2/M phase) to LXL docking sequence in its transcriptional activation 
domain. Upon binding, Cdk is phosphorylated, hence mediating recruitment of the CBP co-
activator protein.  Medema and colleagues identified a couple of downstream target genes of 
FOXM1 that regulate G2/M phase progression. This includes CENP-F, Aurora B kinase, 
Polo-like-kinase (Plk1), Cdc25b phosphatase and cyclin B genes (Costa 2005). 
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1.8.2 FOXA1 
 
FOXA1 or previously known as hepatocyte nuclear factor 3α (HNF3α) was identified as a 
hepatocyte enriched transcription factor which is required for high-level expression of 
transthyretin and a1-antitrypsin gene in the liver (Nakshatri and Badve 2009). FOXA2 
(HNF3β) and FOXA3 (HNF3γ) which also belongs to the subfamily of FOXA were 
subsequently identified. FOXA family regulates the expression of their targeted genes by 
binding to the TGTTTGPy or TGTTTGCT motif in the promoter/enhancer regions. FOXA1 
is recognized as a „pioneer factor‟ due to its structural properties that enables it to bind to 
compacted chromatin. The presence of DNA binding domain of FOXA1 which has structural 
similarity to histone H5 and the interaction of its C-terminus with histones H3 and H4 allows 
it to bind to condensed chromatin, opening the chromatin thus enhancing the recruitment and 
binding of other transcription factors to its target genes (Nakshatri and Badve 2007; Habashy, 
Powe et al. 2008). 
The role of FOXA1 in breast cancer was established only in 2005 where a good correlation 
between FOXA1 expression and ERα-positive breast cancer cell lines were detected 
(Nakshatri and Badve 2007; Nakshatri and Badve 2009). Previous studies have shown the 
involvement of FOXA1 in the recruitment of ERα to 50% of ER-regulated genes indicating 
an important role of FOXA1 in the regulation of ERα. FOXA1 was identified as a direct 
target of ERα where the presence of its binding sites were located in TFF1 or better known as 
pS2 gene which is strongly regulated by ERα (Laganière, Deblois et al. 2005). FOXA1 has 
been shown to play dual roles as tumor promoter and tumor suppressor. As a growth 
stimulator, it promotes estrogen-dependent cell proliferation in breast cancer cells while as a 
repressor; it regulates cell cycle inhibitor p27kip1 and cell adhesion E-cadherin expression 
that prevents the metastatic progression of breast cancer cells (Nakshatri and Badve 2007; 
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Habashy, Powe et al. 2008). Breast cancer can be classified into 5 distinct groups: luminal A, 
luminal B, ERα-negative/HER2-positive, basal type and normal-like (Nakshatri and Badve 
2009). Luminal A and luminal B subtypes are ERα-positive breast cancer. Higher levels of 
ERα are expressed in luminal A subtype breast cancer which shows better prognosis 
compared to luminal B subtype breast cancer.  The classifications of breast cancer could 
either be of prognostic significance or reflecting cell-lineage specific origin of breast cancer. 
For instance, transcriptional activation of ERα is important for cell growth therefore, may be 
important for the survival of luminal A subtype breast cancers (Nakshatri and Badve 2007). 
Recent studies have shown a strong correlation between FOXA1 and ERα expression 
whereby FOXA1 is required for the function of ERα. Consequently, tumours expressing 
FOXA1 are most likely to be target for luminal A subtype breast cancer (Nakshatri and 
Badve 2007; Thorat, Marchio et al. 2008). 
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Figure 1.9: Role of FOXA1 in ERα regulation  
 
FOXA1 has a unique ability to bind to condensed chromatin which enhances the recruitment 
and binding of other transcription factors to its target genes. In context of ERα function, 
binding of FOXA1 to ERα regulated genes may facilitate the opening of condensed 
chromatin which leads to DNA binding of liganded ERα to its target genes (Nakshatri and 
Badve 2007). 
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Figure 1.10: Breast cancer classifications  
 
Breast cancer was classified to five intrinsic subtypes based on microarray analysis by Sørlie, 
Perou et al. 2001. The classifications were mainly based on the levels of ERα expression in 
the breast carcinoma samples. The right branch consists of three subgroups which are defined 
by low to absent ERα expression while the subgroups in the left branch are categorized based 
on high, low to moderate ERα expression. Besides classifying breast cancer based on ERα 
expression, the expression levels of several additional transcriptional factors and gene 
expression patterns further lead to characterization of breast tumors into distinct entities. The 
p53 mutation status is associated with prognosis factor and survival rate (Nakshatri and 
Badve 2007). 
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1.8.3 FOXC2 
 
The FOXC transcription factor is essential for vascular formation and maturation. FOXC1 
and FOXC2 through stimulation of vascular endothelial growth factor (VEGF) expression are 
required for lymphatic sprouting during vascular development (Myatt and Lam 2007). 
FOXC2 gene or previously termed as Mesenchyme Forkhead 1 (MFH-1) belongs to the 
Forkhead/ Fox family of transcription factors which have been reported to be involved as a 
central mediator of the epithelial mesenchymal transition (EMT) process. It is expressed 
mainly in mesoderm and mesoderm-derived tissues where it cannot be detected in any adult 
tissues except for those containing fat cells. During EMT, cells that lose its contact and 
polarity acquire mesenchymal gene expression which leads to changes in their cytoskeleton 
thus exhibiting a mesenchymal appearance with increased motility and invasiveness (Mani, 
Yang et al. 2007). Previous studies have shown that FOXC2 expression is up-regulated in 
metastatic cancer cells and is also associated with aggressive basal-like breast cancers (Mani, 
Yang et al. 2007; Myatt and Lam 2007). 
 
1.9 Activator Protein-2γ (AP-2γ) 
 
The activator protein-2 (AP-2) transcription factors consist of a family of highly homologous 
proteins. There are five AP-2 genes namely AP-2α, AP-2β, AP-2γ, AP-2δ and AP-2ε in 
mammals (Orso, Cottone et al. 2004; Pellikainen and Kosma 2007). AP-2 family members 
can bind as homodimers and heterodimers to GC rich DNA sequences through a highly 
conserved basic helical DNA-binding domain and a dimerization domain. Among the AP-2 
family members, AP-2α, AP-2β and AP-2γ can be classified together based on their sequence 
conservation and expression pattern while AP-2δ and AP-2ε are classified independently. As 
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transcription factors, AP-2 proteins play a vital role in development, growth, differentiation 
and cell death (Li, Goswami et al. 2006; Pellikainen and Kosma 2007). AP-2α deficient mice 
showed multiple neural deformities while loss of AP-2β resulted in incomplete renal 
differentiation. Mice lacking AP-2γ showed the importance of AP-2γ in early embryogenesis 
(Orso, Cottone et al. 2004; Pellikainen and Kosma 2007; Gee, Eloranta et al. 2009).
 
In 
contrast to normal cell development, AP-2 proteins may also contribute to the development 
and progression of endometrial and breast cancers as it is involved in the regulation of c-
erbB-2, E-cadherin, gelatinase A, heat shock protein, insulin growth factor-1 receptor and ER 
expression (McPherson and Weigel 1999). Among the members of the AP-2 protein, the role 
of AP-2α and AP-2γ in breast cancer is being studied extensively. AP-2α expression is 
associated with reduced cell proliferation and better prognosis in breast cancer (Williams, 
Scibetta et al. 2009). AP-2γ has been shown to contribute to the initiation and progression of 
breast cancer via regulation of ErbB2 (HER-2/neu) and ERα (Li, Goswami et al. 2006). The 
mRNA expression of AP-2γ increased upon treatment of oestrogen in ER positive breast 
cancer cells suggesting AP-2γ may be the primary oestrogen responsive gene (Pellikainen 
and Kosma 2007). On the other hand, AP-2γ regulates ERα expression by directly binding to 
the promoter and indirectly via regulation of FOXM1 (Woodfield, Horan et al. 2007). 
Growing evidence suggests that AP-2γ might be linked with increased cell proliferation, 
disease progression and endocrine resistance in breast cancer (Williams, Scibetta et al. 2009). 
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1.10   Treatment 
 
1.10.1 Tamoxifen 
 
The anti-oestrogen tamoxifen which is a non-steroidal Selective Oestrogen Receptor 
Modulator (SERM) is the most commonly used drug to treat breast cancer patients at all 
stages. Tamoxifen inhibits breast cancer growth mainly through competitive binding to the 
ER, inhibiting oestrogen dependent cell growth. This anti-oestrogen treatment results in a 40–
50% reduction of recurrence and leads to prolonged disease-free and overall survival rate. 
However, patients who initially respond to this treatment eventually acquire resistance 
towards tamoxifen, hence leading to tumour progression and death (Schiff, Massarweh et al. 
2003). Patients that develop resistance to tamoxifen do not loss ERα expression as 
approximately 20% of them tend respond to second line therapy such as Aromatase Inhibitors 
or fulvestrant (Normanno, Di Maio et al. 2005; Yue, Fan et al. 2007). 
 
 
Figure 1.11: Structure of Tamoxifen and its metabolites in humans (Osborne 1998) 
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1.10.2 Fulvestrant (ICI 182780) 
 
 
ICI 182780 is a “pure” anti-oestrogen that was first identified in the mid-1980 (Goldstein 
1998). Its non-agonist steroidal characteristics differ from the existing tamoxifen and other 
non-steroidal anti-oestrogens. ICI 182780 is classified as selective oestrogen receptor 
downregulators (SERDs) as it degrades ER rapidly hence leading to complete abrogation of 
ER function (Howell 2000; Fan, Rickert et al. 2007). It has been established that patients 
undergoing adjuvant tamoxifen therapy acquire resistance to this drug but remain ER 
positive. The presence of ER in these patients tends to respond to second line therapy such as 
ICI 182780 (Fan, Rickert et al. 2007). It has been shown that 37% of patients responded 
partially to ICI 182780 while 32% showed disease stabilization in a small phase II study of 
19 postmenopausal patients with advanced breast cancer that did not respond to tamoxifen 
treatment. Extensive clinical studies are taking place to further validate the effectiveness of 
ICI 182780 in patients who are resistant to tamoxifen or as a first-line endocrine therapy 
replacing tamoxifen (Howell 2000). 
 
      
 
Figure 1.12: Structure of fulvestrant (ICI 182780) (Fan, Rickert et al. 2007) 
 
 
 
 
  
46 
1.11 Endocrine Resistance 
 
Endocrine therapy is the first line of therapy to treat patients with breast cancer. Anti-
oestrogen drug, tamoxifen has been the ultimate choice of treatment for over thirty years. The 
incidence of annual recurrence and death for breast cancer are reduced by 47% and 26% 
respectively following five years of adjuvant tamoxifen therapy (Zilli, Grassadonia et al. 
2009). Patients who are de novo tamoxifen resistant would not respond to tamoxifen. Almost 
all patients with advanced breast cancer who respond to tamoxifen treatment initially will 
eventually develop resistance to the drug (Shao and Brown 2004). 
 
Since oestrogen mediates its effect through ER in normal breast development, increased 
exposure to oestrogen is implicated in breast cancer pathogenesis (Ghosh, Thompson et al. 
2000). As a result, drugs have been designed to reduce the circulating oestrogen levels or 
inhibit ER signalling in breast cancer (Zilli, Grassadonia et al. 2009). However the 
occurrence of tamoxifen resistance has been a limiting factor in endocrine therapy. As ERα is 
currently the principal predictive biomarker in the management of breast cancer patients, loss 
of its expression or ERα mutations might be potential mechanisms of acquired resistance. 
However, only 15-20% of resistant breast cancers do not express ERα while ERα mutations 
occur in <1% of ERα-positive tumours (Musgrove and Sutherland 2009). Increasing evidence 
shows the importance of co-regulators in influencing ERα-mediated transcription and 
tamoxifen-mediated response in normal breast development and in breast cancer progression, 
respectively (Romano, Adriaens et al. 2010). Over-expression of co-activators and/or down-
regulation of co-repressors can lead to aberrant effects in endocrine therapy such as reduced 
tamoxifen responsiveness in breast cancer patients (Musgrove and Sutherland 2009; Romano, 
Adriaens et al. 2010). Growth factors such as epidermal growth factor (EGF) or insulin-like 
growth factor families and hormones such as insulin, bind to their respective receptors and 
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initiate kinase-signalling cascade followed by activation of intracellular signalling molecules. 
These signalling pathways include PI3K/Akt pathway which is involved in cell survival and 
MAP kinase pathway which mediates cell proliferation. It is evident that bi-directional cross-
talks between ERα and growth factor signalling pathways augments the cell proliferation and 
survival signals in breast cancer. In addition, up-regulation of growth factor signalling 
pathways in the presence of increased levels of ERα co-activators can lead to tamoxifen 
resistance in breast cancer patients (Osborne and Schiff 2003). Therefore, by targeting the 
growth factor signalling pathways and ERα co-regulators, tamoxifen‟s antagonist activity 
could be restored and this probably would overcome the phenomenon of tamoxifen resistance 
in breast cancer patients. However, other possible mechanisms contributing to endocrine 
resistance also have been suggested. It is important to identify groups of patients who will 
benefit from different drugs; hence there is a need for new molecular and clinical data that 
will aid in understanding the mechanisms involved.  
 
 
 
Loss of expression or altered function (mutations) of ERα 
Lack of expression of PgR 
Increased expression of ERβ 
Metabolism of hormonal agents (CYP2D6 variants for tamoxifen) 
Altered expression of co-regulators 
Oestrogen hypersensitivity 
Oestrogen supersensitivity 
Increased growth factor signalling                                 
       (Normanno, Di Maio et al. 2005) 
 
 
Table 1.1: Modified ERα expression 
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THESIS AIMS AND HYPOTHESES 
 
 
 
AIMS 
 
 
1. To determine the role of AP-2γ in regulating FOXM1 expression mediating ER 
signals in endocrine sensitive and resistant breast cancer cells. 
 
2. To determine the role of Forkhead box (Fox) proteins in endocrine sensitive and 
resistant breast cancer. 
 
 
HYPOTHESES  
 
 
 
1 AP-2γ regulates FOXM1 expression in breast cancer. 
 
2 Deregulation of Forkhead transcription factors will overcome the dependency of breast 
cancer on oestradiol for cell proliferation and survival. 
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2 CHAPTER 2: MATERIALS AND METHODS 
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2.1 Cell Lines 
 
The non-malignant MCF-10A, HBL-100 and malignant human breast cell lines MCF-7, ZR-
75–1, ZR-75–30, CAMA1, BT-474, MDA-MB-453, T47-D, CAL-51, SKBR-3, MDA-MB-
468, BT-549 and MDA-MB-231 were originally obtained from the American Type Culture 
Collection (ATCC).  MCF-7 derived tamoxifen resistant cell lines, MCF-7/TAM
R
-4 and 
MCF-7/TAM
R
-7 were a gift from Dr. Anne E. Lykkesfeldt and have been previously 
described in (Lykkesfeldt, Madsen et al. 1994; Madsen, Reiter et al. 1997). MCF-7 derived 
MLET cell lines (MLET1, MLET2, and MLET5) were a generous gift from Dr. Laki 
Buluwela (Imperial College, London). It was established from prolong culturing of 
adenovirally infected MCF-7 cells in oestrogen-free conditions. 
 
2.2 Cell Culture 
 
All the procedures were carried out in a sterile condition using a Class 11 biohazard cabinet 
and aseptic techniques were practiced. Good cell culture practice (GCCP) guidelines were 
applied during conducting the experiments. The human breast carcinoma cells were routinely 
cultured in phenol red Dulbecco‟s Modified Eagle‟s Medium (DMEM, Sigma, UK) 
supplemented with 10% Foetal Calf Serum (FCS, First Link Ltd.UK) while the MLET cell 
lines were grown in phenol-red-free DMEM, 1X (Gibco-Invitrogen, UK) supplemented with 
5% Double Charcoal Stripped Foetal Calf Serum (DCS FCS, First Link Ltd.UK) plus 100 
U/ml penicillin/streptomycin and 2 mM glutamine respectively (Gibco-Invitrogen, UK). 
TamR cell lines were cultured in phenol-red-free DMEM/F-12 (Gibco-Invitrogen, UK) 
supplemented with 5% Double Charcoal Stripped Foetal Calf Serum (DCS FCS, First Link 
Ltd.UK) plus 100 U/ml penicillin/streptomycin, insulin (Sigma, UK) and routinely 
maintained in the presence of 4-hydroxytamoxifen (4-OHT). 4-OHT was obtained from 
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Sigma, UK, dissolved in ethanol and used at a final concentration of 500nM. Cells were 
maintained at 37°C under 10% CO2  in a humidified atmosphere.   
 
2.3 Drug Treatment 
 
MCF-7, MLETs, R4 and R7 cells were either cultured in a 6-well plate or 10cm
2 
petri dish. 
These cells were treated with either 4-OHT (Sigma), 500nM in ethanol or Fulvestrant (ICI 
182780), 1x10
-7 
M in ethanol for 0, 8, 24, 48 or 72 hours. 0 hour was used as control without 
any treatment.  
 
2.4 Plasmids and Transfections 
 
The human FOXM1 promoter constructs ApaI, PvuI, and FOXM1_wt in pFlash reporter 
vectors were gifts from Professor Rene H. Medema (University Medical Center Utrecht, The 
Netherlands) and has been previously described in (Korver, Roose et al. 1997). These 
promoter constructs were then subcloned into the pGL3-basic reporter vector (Promega) 
using their original cloning sites. The FOXM1 expression vector contains a full-length 
FOXM1 cDNA cloned into pcDNA3.1 (Invitrogen) that has been described previously in 
(Madureira, Varshochi et al. 2006). The human AP-2γ plasmid was a generous gift from 
Professor Helen Hurst (Center for Tumour Biology, Institute of Cancer, Bart‟s and The 
London School of Medicine and Dentistry, Charterhouse Square, London) and has been 
previously described in (Gee, Eloranta et al. 2009). The human FOXA1 plasmid and ERα 
expression construct pHEG0 were generated in Professor Eric Lam‟s lab.   
 
For transfections, cells were seeded to an approximately 50% confluency and incubated with 
a master mix of transfection reagents containing Fugene
® 
6 Transfection Reagent as 
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instructed by the manufacturer (Roche, UK) and the plasmid DNA in a ratio of 3:1 or 3:2 
diluted in serum free media or Opti-MEM. Cells were grown for 48 hours before use. 
 
2.5 Plasmid Transformation and DNA Extraction 
 
Plasmids of interest were amplified in competent bacteria cells to make large quantities. 1µl 
(100ng) of plasmid were added to 10 µl of competent cells (NovaBlue) in an eppendorf tube 
which were then placed on ice for 30 minutes. Bacteria cells underwent heat shock at 40°C 
for 45 seconds and were kept on ice for 2-3 minutes. 150 µl LB media (Tryptone, yeast 
extract and NaCl) were added to the mix and kept on the shaker for 15-20 minutes at room 
temperature. The transformation mixtures were spread on a labelled agar plates containing 
ampicilin (100 μg/ml, Sigma) using a sterilized, bent glass rod spreader. The plates were 
placed in the 37°C incubator overnight. A single colony was picked and grown in a conical 
flask containing appropriate LB media and ampicilin (100μg/ml) under vigorous shaking for 
16 hours. Bacterial cells were harvested and DNA was eluted using the HiSpeed Plasmid 
Maxi Kit (Qiagen, UK). 
 
2.5.1 DNA Measurement 
 
DNA concentration was determined using ND-1000 spectrophotometer (NanoDrop 
Technologies).1μl of each sample was used to measure the DNA concentration (ng/μl). 
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2.6 Luciferase Reporter Assay 
 
Cells were cultured in 96-wells plates until they reached a desired density of 50% confluency.  
Cells were transfected with human FOXM1 promoter, human AP-2γ plasmid and Renilla 
(pRL-TK; Promega, Southampton, UK) for 24 hours. Transfection reagent used in this 
experiment was Fugene
® 
6 Transfection Reagent as instructed by the manufacturer (Roche, 
UK). For promoter analysis, 24 hour after transfection, cells were washed with PBS and 
lyzed with 100μl mixture of Luciferase Reagent (one vial of luclite luciferase reagent, Luclite 
buffer (Perkin ElmerTM Life Sciences), 1M MgCl2, 2.5M CaCl2) and PBS in each well. 
After incubation for 15 minutes at room temperature, cells were transferred to an OptiPlate-
96 (Perkin ElmerTM Life Sciences) to measure the firefly luciferase activity. After 
quantification of firefly luminescence, the reaction was quenched and the Renilla luciferase 
reaction was initiated by addition of 25μl of Renlite reagent [Renilla buffer: HEPES (0.5M, 
pH 7.8), EDTA (0.5M) and Coelenterazine (1mg/ml)]. Cells were incubated at room 
temperature for 20 minutes before reading was taken. Both the readings were done using 
TopCount Luminometer (Perkin ElmerTM Life Sciences). Each sample was normalized by 
dividing firefly luciferase as the test reporter activity by the internal control Renilla 
luciferase. The Dual-Luciferase reporter assay system (Promega, Southampton, UK) is an 
efficient system as it performs dual-reporter assays where the activities of firefly and Renilla 
luciferase are measured sequentially from a single sample. Other transfection reagent such as 
Lipofectamine (Invitrogen Ltd, UK) was used to transfect cells that had lower transfection 
efficiency to Fugene
® 
6. 
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2.7 Protein Studies 
 
2.7.1 Protein Cell Lysis 
 
Cells that were cultured to determine a particular protein expression were washed with ice-
cold Phosphate Buffered Saline (PBS) and lysed using ice-cold lysis buffer (200mM NaCl, 
50mM Tris-HCl pH 7.4, 2mM EDTA, 1% Triton X-100, 10% Glycerol with an addition of 
10mM NaF, 1mM Na3VO4 and protease inhibitors (Complete protease inhibitor mixture, as 
instructed by the manufacturer, Roche Applied Science, Lewes, UK).  Harvested cells were 
placed on ice for 15 minutes. Insoluble material was removed by centrifugation at 14,000 rpm 
for 5 minutes at 4°C. The supernatant was then transferred into a clean eppendorf and stored 
at -80°C until required. All the procedures were performed on ice. 
 
2.7.2  Protein Concentration Assay  
 
The Bio-Rad DC (Bio-Rad, Hemel Hempstead, UK) protein assay was used to determine the 
protein concentration of the lysed samples. 20μl of Reagent S was added to 1ml of Reagent 
A.100μl of the mix was transferred to each disposable polystyrene cuvettes followed by the 
2μl of lysate that were added to the respective cuvettes. Finally, 800μl of Reagent B were 
added to each cuvette. The reagents and samples were mixed well and incubated for 15 
minutes before the readings were taken. A spectrophotometer was used to measure the 
protein concentration at wavelength of 750nm using the Lowry method. Before the samples 
were placed in the spectrophotometer, a blank (a reference cuvette that does not contain any 
sample) was used to calibrate the spectrophotometer. Protein concentration was determined 
by multiplying the absorbance of the sample by the standard curve‟s regression co-efficient. 
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2.7.3 Western Blotting 
 
Once the concentrations were determined, proteins were subjected to electrophoresis 
separation using Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis (SDS-PAGE). 
Gel preparation was based on the size of protein of interest. Higher percentages of gels (w/v) 
were used for smaller protein sizes while lower percentages of gels were used for bigger 
protein sizes. 7 % (w/v) or 10% (w/v) of SDS-PAGE gels were used where an equal volume 
of protein sample (25μg) and loading dye (2X) [1.5M Tris pH 6.8, 10% sodium dodecyl 
sulfate (SDS), 20% glycerol, 0.2% bromophenol blue, 100µl/ml Dithiothreitol (DTT)] were 
loaded into each well. 5μl of Amersham rainbow marker (GE Healthcare Ltd, UK) was also 
loaded in either ends of the gels to enable in identifying the size of the protein of interest. The 
gel was run at 80V in Running Buffer for approximately 2 hours. Proteins were then trans-
blotted onto a Protran nitrocellulose membrane (Schleicher and Schuell, Whatman, 
Brentford, UK) for 1 hour and half at 90V. Once the transfer ended, Ponceau-S (Sigma) 
staining reagent was used to determine the transfer efficiency where the proteins bands can be 
visualised. The membranes were destained with Tris buffered solution with 0.05% Tween-20 
(TBS-T) and then blocked with either 5% (w/v) dry milk in TBS-T solution or 5% (w/v) 
bovine serum albumin (BSA) dissolved in TBS-T solution for 1 hour at room temperature. 
The choice of blocking solution varies according to the protein of interest. Milk is not 
recommended for studies of phosphoprotein as milk contains casein which is phosphoprotein. 
After blocking, the membranes were washed with TBS-T solution for 5 minutes before 
incubating with a primary antibody overnight at the cold room. After incubation with primary 
antibody, membranes were washed with TBS-T solution 5x every 15 minutes followed by 
incubation of the secondary antibody between 20 minutes to 45 minutes at room temperature 
based on the type of antibody. The secondary antibody is directed at a species-specific 
portion the primary antibody and often referred as "anti-rabbit and" "anti-goat".The 
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membranes were then washed with TBS-T solution 6x every 15 minutes. Primary antibodies 
were prepared in a dilution of 1:1000 in 5% BSA while secondary antibodies were diluted in 
1:3000 in TBS-T solution. Primary antibodies were detected using horseradish peroxidise 
(HRP) linked anti-rabbit and anti mouse conjugates by  using the Enhanced Chemi-
luminescence reagent (ECL, GE Healthcare) at various exposures to obtain the most desired 
appearance of the protein of interest.   
 Resolving gel Stacking 
5% 7% 10% 12% 14% 5% 
dH2O 5.68 5.02 4.02 3.35 2.68 3.67 
1.5M Tris pH 8.8 2.5 2.5 2.5 2.5 2.5  
1.5M Tris pH 6.8      0.42 
30% Acrylamide/0.8% Bis 
mix (37.5:1) 
1.67 2.33 4.00 4.00 4.67 0.83 
10% SDS (µl) 100 100 100 100 100 50 
25% APS (µl) 40 40 40 40 40 20 
TEMED (µl) [5-15] 10 10 10 10 10 10 
Total (ml) 10 10 10 10 10 5 
 
Table 2.1: Composition of various percentages of SDS-PAGE  
 
 
2.7.4 Antibodies  
 
Several primary and secondary antibodies were used in Western blotting. β-Tubulin was used 
as loading control for Western Blotting. These include:  
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Antibody (clone) Species Company 
FOXM1(C-20) Rabbit polyclonal  Santa Cruz Biotechnology 
ERα (HC-20)  Rabbit polyclonal  Santa Cruz Biotechnology 
AP-2γ (6E4) Mouse monoclonal  Generated by Professor 
Helen Hurst and group 
(JMW Gee 2009) 
 
FOXA1 (ab23738) Rabbit polyclonal Abcam 
FOXC2 (F1054) Rabbit polyclonal  Sigma-Aldrich 
β-Tubulin (H-35) Rabbit polyclonal  Santa Cruz Biotechnology 
Polyclonal  Goat Anti-Rabbit 
Immunoglobulins/HRP 
 
 Dako,Denmark 
Polyclonal  Goat Anti-Mouse 
Immunoglobulins/HRP 
 
 Dako,Denmark 
 
Table 2.2: Primary and secondary antibodies for western blotting 
 
2.8 RNA Studies 
 
2.8.1 RNA Extraction 
 
Cells grown and treated with respective drugs and time points were washed with PBS 
followed by trypsinization with 1X trypsin in EDTA (Sigma) and centrifuged at 300 x g for 5 
minutes. The supernatant was completely aspirated leaving the pellet for lysis. At this stage, 
the pellet can be either extracted or frozen at -80°C. The total RNA was isolated using the 
RNeasy kit (Qiagen, UK) according to the manufacturer‟s instructions. 
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2.8.2 RNA Measurement  
 
RNA was quantified using ND-1000 spectrophotometer (NanoDrop Technologies).1 μl of 
each sample was used to measure the RNA concentration (ng/μl). 
 
2.8.3 cDNA Synthesis and Real-Time quantitative PCR (RT-qPCR) 
 
2μg of total RNA was reverse-transcribed using the Superscript First-Strand Synthesis 
System for RTq-PCR (Invitrogen Ltd, UK). The resulting cDNA samples were first diluted in 
1:2 to make the serial dilutions (1:1, 1:4, 1:16, 1:64 and 1:256) for the standard curve. The 
cDNA samples that were first diluted 1:2 were further diluted 1:8 for the samples. 25μl of 
reaction mix of Power SYBR
®
 Green PCR Master Mix (Applied Biosystems, UK), Reverse 
Primer (R), Forward Primer (F), cDNA and RNAse free water were prepared to run the RTq-
PCR. The samples and blank (RTq-PCR mix with RNAse free water instead of cDNA) were 
done in triplicate while the standard curve was done in duplicate. The sequences of the 
optimized primer sets used for each analysis are stated below. L19, a non-regulated ribosomal 
housekeeping gene was used as an internal
 
control and to normalize mRNA quantification 
target for differences in input RNA. Detection of FOXM1, ERα, AP-2γ and FOXA1 mRNA 
transcription was performed in Applied Biosystems 7900HT Fast Real-Time PCR System 
and 7300/7500 Real-Time PCR Systems machine. All the procedures above were carried out 
in RNase free water condition.  Efficiency of PCR was obtained from the slope of the 
standard curve. 
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2.8.4 Primer Optimization 
 
AP-2γ sequence was obtained from Ensembl while the primer pairs were designed using the 
ABI Primer Express Software. A standard optimization method was performed to obtain 
appropriate primer concentrations as it is essential for maximal specificity and efficiency in 
PCR. 2μg of total RNA that were reversed-transcribed into cDNA was used to perform the 
optimization. A combination of the 3 different forward and reverse primers concentrations 
were tested. The minimum primer concentration was determined as it yields minimum CT and 
maximum ΔRn value. 
 
                 Forward  
                  Primer 
Reverse  
Primer 
 
50 (nM) 300 (nM) 900 (nM) 
50 (nM) 50F 50R 300F 50R 900F 50R 
300 (nM) 50F 300R 300F 300R 900F 300R 
900 (nM) 50F 900R 300F 900R 900F 900R 
 
Table 2.3: Combinations of primer concentrations for optimization 
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Primer Sequence 
FOXM1 
Forward:  
5'- TGCAGCTAGGGATGTGAATCTTC -3' 
Reverse: 
5'- GGAGCCCAGTCCATCAGAACT -3' 
ERα 
Forward:  
5'- TGATCAGGTCCACCTTCTAGAATG-3' 
Reverse: 
5'- CGCCAGACGAGACCAATCAT-3' 
Ap-2γ 
Forward:  
5'- AAATGAGATGGCAGCTAGGAAGA -3' 
Reverse: 
5'- TTGGCTGAGAAGTTCTGTGAATTC -3' 
FOXA1 
Forward:  
5'-GCTGGACTTCAAGGCATACGA -3' 
Reverse: 
5'-GGCAACGTAGAGCCGTAAGG -3' 
L19 
Forward:  
5'- GCGGAAGGGTACAGCCAAT -3' 
Reverse: 
5'- GCAGCCGGCGCAAA -3' 
 
Table 2.4: Primer sequences for FOXM1, ERα, Ap-2γ, FOXA1, and L19  
 
2.9 Small Interfering RNA (siRNA) 
 
RNA interference (RNAi) is an evolutionarily conserved cellular defence system for 
controlling foreign gene expression in humans and other organisms (first discovered in 
plants) (Tuschl and Borkhardt 2002). siRNA (silencing RNA) is involved in the RNAi 
pathway, where it interferes with expression of a specific gene. In this study, the expression 
of AP-2γ gene was silenced using ON-TARGETplus SMARTpool (5nmol) (Dharmacon, 
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RNAi technologies) and Oligofectamine (Invitrogen Ltd, UK) was used as a transfection 
reagent. A day before transfection, cells were cultured in a 6-well plate for 24 hours. On the 
day of transfection, 2 separate tubes (A and B) were prepared each for mock-transfection (no 
siRNA), positive control siRNA (siRNA targeting endogenous AP-2γ gene (L-005238-00), 
ERα gene (L-003401-00) and FOXA1 gene (L-010319-00) and negative control siRNA (non-
targeting/non-specific siRNA) respectively. In tube A, 120μl OPTI-MEM® (Gibco-
Invitrogen) and 10μl Oligofectamine were mixed and incubated for 10 minutes at room 
temperature. In tube B, 535μl OPTI-MEM® and 15μl 1X buffer were mixed and incubated for 
15 minutes at room temperature. 15μl siRNA (50μM final concentration) and 15μl non-
specific siRNA were added for the positive control tube and negative control tube 
respectively instead of 1X buffer. Both the contents, A and B were mixed and incubated for 
another 25 minutes at room temperature. 320μl of OPTI-MEM®  was added to the mixture to 
make up a total volume of 1ml. Cells were washed with PBS followed by addition of 500μl 
of mix to each respective wells and then incubated at 37°C in 10% CO2 for 4 hours. 2ml of 
media were added after incubation. Cells were harvested at 48 and 72 hours time point for 
protein and mRNA analysis.  
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2.10   Statistical Analysis 
  
 
The GraphPad Prism Software version 5.01 was used for statistical evaluation. One-way 
analysis of variance (ANOVA) was performed followed by two-tailed Dunnett‟s t test to 
analyze differences in expression levels while Student‟s t test was employed to test the 
differences between samples. The mean difference was considered statistically significant 
when p values were < 0.05. The asterisks (*) in each graph indicates statistically significant 
changes.  
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3 CHAPTER 3: AP-2γ REGULATES FOXM1 EXPRESSION
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3.1 INTRODUCTION 
 
 
Transcription factors are classified as one of the most important gene regulatory proteins with 
sequence-specific DNA recognition sites. They have major influence on target genes and 
their functions in normal cellular processes by up-regulating and down-regulating their 
expressions. Transcription factors are required for almost every primary developmental and 
homeostatic process in organisms including DNA replication and repair, cell proliferation, 
cell differentiation and programmed cell death (apoptosis). Therefore, it is not surprising that 
transcription factor dysfunction can contribute to human carcinogenesis (Benz 1998). 
 
Many transcription factors have been identified to play crucial roles in breast cancer 
development. Several studies have shown that Activator protein-2 (AP-2) might be involved 
in cell cycle progression by activating proliferation-specific genes and inhibiting 
differentiation-specific markers during development. Among the AP-2 family members, AP-
2γ gene is found to be highly expressed in breast cancer cell lines (Jäger, Werling et al. 
2003). Another transcription factor that is widely recognized in promoting cell proliferation 
by regulating cell cycle genes is FOXM1. This transcription factor is also found to be over-
expressed in breast cancer (Zeng, Wang et al. 2009). Recent studies revealed the role of AP-
2γ and ERα in oestrogen signalling pathways where AP-2γ regulates ERα by directly binding 
to its promoter and indirectly via FOXM1 regulation (Woodfield, Horan et al. 2007). It would 
be interesting to elucidate the interaction of two important transcription factors, AP-2γ and 
FOXM1 and the importance of ERα in this interaction in breast cancer cell lines. 
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3.2 RESULTS 
 
 
3.2.1 AP-2γ expression associates with FOXM1 expression in breast     
            carcinoma cell lines 
 
To test the hypothesis that AP-2γ regulates FOXM1 expression, western blot analysis was 
performed on a panel of 14 different breast cell lines. As shown in Figure 3.1, the results 
indicated a positive association between the levels of AP-2γ and FOXM1 expression in 4 out 
14 breast carcinoma cell lines. Interestingly, ERα was found to be highly expressed in 2 out 
of the 4 breast carcinoma cell lines (MCF-7 and T-47D) suggesting its role in the regulation 
of AP-2γ and FOXM1. It has been previously shown that ERα-positive ZR-75-1 cell line 
expresses AP-2γ which positively regulates ERα (Woodfield, Horan et al. 2007). A similar 
expression pattern was expected but it showed negative association.  
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Figure 3.1: AP-2γ and FOXM1 expressions in a panel of breast cell lines 
Western blot analysis was performed using specific antibodies against AP-2γ, FOXM1, ERα 
and β-tubulin and their associations were examined. β-tubulin was used as loading control. 
„+‟ indicates positive relationship and „-‟ indicates negative relationship for each cell line. 
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3.2.2 AP-2γ represses FOXM1 at gene promoter level 
 
As described in Figure 3.1, AP-2γ expression correlated with FOXM1 expression in MCF-7, 
MDA-MB-453, MDA-MB-468 and T-47D breast carcinoma cell lines. Reporter gene assays 
were performed on MCF-7 cells to further explore the regulation of AP-2γ on FOXM1 
promoter activity. Wild-type and truncated FOXM1 luciferase promoter constructs (PvuI and 
ApaI) were co-transfected with pcDNA3-AP-2γ or pcDNA3 into MCF-7 cells for 24 hours. 
Renilla (pRL-TK) was also co-transfected in all experiments where the Renilla luciferase 
activity was used to normalize the transfection efficiency. The transfection results showed a 
significant repression of FOXM1 promoter activity in the truncated promoter constructs 
(PvuI and ApaI), with increasing concentrations of AP-2γ (Figure 3.2). 
 
It has been shown previously that ERα regulates FOXM1 by binding to its consensus 
Estrogen Response Elements (EREs) which are present in the FOXM1 promoter and AP-2γ 
regulates ERα by binding directly to its promoter (Woodfield, Horan et al. 2007; Millour, 
Constantinidou et al. 2010).  ERα is known to be highly expressed in MCF-7 cells and it was 
important to identify whether ERα plays a role in the regulation of AP-2γ and FOXM1. 
Certain regions in the consensus ERE FOXM1 promoter construct (ApaI) were mutated to 
generate mutant EREs; pGL3 basic mERE3 FOXM1 (ApaI) and pGL3 basic mERE4 
FOXM1 (ApaI). Transient transfection of MCF-7 cells with the full length and truncated 
FOXM1 promoter constructs in the presence of ERE consensus binding sites, showed a 
decrease in promoter activity whereas the opposite effects were observed in the mutant EREs. 
As seen in Figure 3.3, titration of AP-2γ activated mutant ERE3 and ERE4 activity compared 
to control ApaI promoter. The promoter results suggest that repression of FOXM1 activity by 
AP-2γ might require ERα binding to its ERE consensus sites on FOXM1 promoter.  
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Figure 3.2: Effect of AP-2γ on FOXM1 promoter activity in MCF-7 cells 
MCF-7 cells were co-transfected with 20ng wild-type or truncated FOXM1 luciferase 
promoter constructs (PvuI and ApaI) with either pcDNA3-AP-2γ or pcDNA3 alone for 24h. 
The relative luciferase activity was normalized with Renilla activity. The bars represent the 
mean values from three independent experiments ± S.E.M, (** p < 0.01, *** p < 0.001; two-
tailed Dunnett‟s t test where 0 ng as control). 
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Figure 3.3: AP-2γ activates mutant FOXM1 (ApaI) promoter activity in MCF-7 cells 
MCF-7 cells were co-transfected with 20ng truncated FOXM1 (ApaI) luciferase promoter 
construct and its mutant constructs (mERE3 and mERE4) with either pcDNA3-AP-2γ or 
pcDNA3 alone for 24h. The relative luciferase activity was normalized with Renilla activity. 
The bars represent the mean values from three independent experiments ± S.E.M,  
(** p < 0.01, *** p < 0.001; two-tailed Dunnett‟s t test where 0 ng as control). 
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3.2.3 Over-expression of AP-2γ activates FOXM1 at protein level  
 
As shown in Figure 3.2, AP-2γ represses FOXM1 promoter activity in MCF-7 cells in a dose-
dependent manner. Next, AP-2γ was transiently over-expressed in MCF-7 cells to examine 
whether AP-2γ represses FOXM1 at mRNA and protein levels. MCF-7 cells were transfected 
with increasing concentrations of AP-2γ for 48 hours. Western blot analysis revealed an 
increase in FOXM1 expression, which contradicted to the promoter level results (Figure 
3.4A). No changes were observed at the levels of FOXM1 mRNA indicating that the increase 
is at translational level (Figure 3.4B). ERα also did not show any changes in transcriptional or 
translational levels.  
 
From the promoter results, it is likely that ERα plays a role in the regulation of AP-2γ and 
FOXM1. Hence, it is important to know whether the repression of FOXM1 by AP-2γ in 
MCF-7 cells is through ERα. To test this, AP-2γ was over-expressed in the ERα-negative and 
low AP-2γ expressed cell line MDA-MB-231 and the expression of FOXM1 was examined. 
High levels of FOXM1 were maintained at protein and mRNA levels regardless of increasing 
AP-2γ concentrations in the absence of ERα in this cell line (Figure 3.4A and Figure 3.4B). 
From these results, it is still unclear whether AP-2γ has a direct or indirect effect on FOXM1 
expression.     
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Figure 3.4: Translational and transcriptional regulation of FOXM1 activity by AP-2γ   
MCF-7 and MDA-MB-231 cells were transiently transfected with increasing amounts (0, 1 
and 2 μg) of AP-2γ for 48h. A, Protein lysates were prepared for Western blot analysis where 
specific antibodies were used to examine protein expression levels. B, Total RNA was 
isolated from MCF-7 (black bars) and MDA-MB-231 (maroon bars) cells that were 
transiently transfected with AP-2γ where mRNA levels of AP-2γ, FOXM1 and ERα were 
analyzed by real-time quantitative PCR normalized with L19 mRNA levels. Average of two 
independent experiments. Mean ± S.E.M, (* p < 0.05, *** p < 0.001; two-tailed Dunnett‟s t 
test where 0 ng as control). 
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3.2.4 Knockdown of AP-2γ by siRNA results in a reduction of FOXM1 
            expression in MCF-7 cells  
 
To identify whether FOXM1 is a direct or indirect target of AP-2γ, endogenous AP-2γ was 
knocked-down by RNA interference. ERα-positive MCF-7 cells were transfected with siRNA 
directed against AP-2γ for 72 hours. Protein expression and mRNA levels of AP-2γ, FOXM1 
and ERα were analyzed by western blotting and RT-qPCR respectively. By 72 hours after 
transfection, elimination of AP-2γ reduced both the expression of FOXM1 and ERα at 
protein and transcriptional levels (Figure 3.5) compared to control (non-targeting siRNA). 
These results were in line previous studies which showed that positive regulation of ERα 
expression is specific for AP-2γ although this was not evident in over-expression studies of 
AP-2 factors in breast cancer (Woodfield, Horan et al. 2007). Reduced FOXM1 expression 
compared to control suggests that the decrease might be a direct effect of AP-2γ knockdown 
or an indirect effect via ERα.  
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Figure 3.5: Knockdown of AP-2γ leads to down-regulation of FOXM1 expression in 
MCF-7 cells 
A, MCF-7 cells were transfected with mock, AP-2γ specific siRNA (Si) and control non-
specific siRNA (NS). After 72 h, Western blotting analysis was conducted. B, Quantitative 
real time PCR of AP-2γ, FOXM1 and ERα expressions was performed on cDNA from MCF-
7 cells. Experiments were repeated twice and represented as Mean ± S.E.M. Statistical 
analysis was done using Student‟s t test, (** p < 0.01, ***p < 0.001). 
 
 
*** 
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3.2.5 AP-2γ and FOXM1 expression in MCF-7 derived anti-oestrogen 
resistant cell lines  
 
A panel of sensitive and anti-oestrogen resistant MCF-7 derived cell lines (MLET1, MLET2, 
MELT5, MCF-7/TAM
R
-4 and MCF-7/TAM
R
-7) were subjected to western blotting to look at 
the association of AP-2γ and FOXM1. These cell lines were either resistant to tamoxifen or 
ICI or both. The MLET1, 2 and 5 cells were established from prolonged culturing of 
adenovirally infected MCF-7 cells in oestrogen-free conditions. As a result, MLET1 and 
MLET 2 lost their ERα expression and showed no sensitivity to oestadiol (E2), anti-oestogens 
such as 4-OHT, Raloxifen or ICI while MLET5 cells continued to express ERα and are 
partially sensitive to E2 and anti-oestrogens. MCF-7/TAM
R
-4 and MCF-7/TAM
R
-7 were 
established from long term treatment with 10
-6
M tamoxifen in MCF-7 cells using a procedure 
that has been previously described (Lykkesfeldt, Madsen et al. 1994; Madsen, Reiter et al. 
1997). 
 
As shown in Figure 3.6, AP-2γ expression associates with FOXM1 expression in the 
sensitive and resistant cell lines at protein and mRNA levels.  ERα was expressed in MCF-7, 
MLET5, MCF-7/TAM
R
-4 and MCF-7/TAM
R
-7 cells with undetectable levels in MLET1 and 
MLET2 cells. These results suggest that high or low levels of ERα, AP-2γ and FOXM1 
transcription factors in these cell lines may contribute to endocrine resistance.  
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Figure 3.6: AP-2γ expression associated with FOXM1 expression in MCF-7 derived 
resistant cell lines 
A, Western blot analysis were carried out on a panel of anti-oestrogen resistant cells lines; 
MLET1 (M1), MLET2 (M2), MLET 5(M5), MCF-7/TAM
R
-4 (R4) and MCF-7/TAM
R
-7 
(R7) which were derived from parental MCF-7 cells. β-tubulin was used as loading control. 
B, mRNA levels of AP-2γ, FOXM1 and ERα were examined using RT-qPCR analysis. 
Experiments were repeated twice and represented as Mean ± S.E.M. 
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3.2.6 Knockdown of AP-2γ in MLET2 cells down-regulates FOXM1 
expression  
 
As described in Figure 3.5, there was a reduction of FOXM1 and ERα expression in MCF-7 
cells at protein and transcriptional levels upon AP-2γ gene knockdown. To further understand 
these findings, AP-2γ was knocked-down by siRNA in MLET2 cells for 72 hours. Protein 
levels of AP-2γ and FOXM1 were examined by western blotting and the transcript levels 
were quantified by RT-qPCR. When MLET2 cells were transfected with AP-2γ-specific 
siRNA, FOXM1 expression was markedly decreased in the absence of ERα at protein and 
mRNA levels (Figure 3.7). These results together suggest that AP-2γ might be involved in 
FOXM1 regulation.   
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Figure 3.7: Knockdown of AP-2γ in MLET2 cells reduces FOXM1 expression  
MLET2 cells were transfected with mock, AP-2γ specific siRNA (Si) and control non-
targeting siRNA (NS). A, Cell lysates were prepared after 72 h transfection and the 
expression of AP-2γ, FOXM1 and β-tubulin was analyzed by Western blot analysis. B, Total 
RNA was extracted from MLET2 cells and RT-qPCR analysis were performed for AP-2γ and 
FOXM1.Experiments were repeated twice and represented as Mean ± S.E.M. Statistical 
analysis was done using Student‟s t test, (** p < 0.01, *** p < 0.001). 
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3.2.7 Effects of reduced serum concentrations on FOXM1 expression 
 
FOXM1 is known for its crucial role in cell proliferation. It is believed that FOXM1 is 
involved in cancer development through cell proliferation stimulation as high levels of 
FOXM1 are detected in cancer cells (Laoukili, Alvarez et al. 2008). Various growth 
conditions can affect cell proliferation in a positive or negative manner thus influencing the 
normal functions of regulatory molecules that are involved in cell growth. To elucidate 
whether endogenous AP-2γ regulates FOXM1, MCF-7 cells were serum starved at different 
concentrations of Foetal Calf Serum (FCS) and Double Charcoal Stripped Foetal Calf Serum 
(DCS FCS) for 24 hours to determine its effect on FOXM1 at protein and levels. The western 
blot results showed an expected decrease in FOXM1 expression at lower levels of serum 
which were more apparent in the presence of DCS FCS compared to FCS. Interestingly, a 
similar result was also observed in ERα at translational levels with no changes in AP-2γ 
expression (Figure 3.8). These results further prove the importance of serum which is a rich 
source of nutrients such as growth factors and hormone that is necessary for the growth and 
proliferation of the cells. Transcription factors that are involved in cell proliferation such as 
FOXM1 and ERα are affected by decreasing serum concentration.  
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Figure 3.8: FOXM1expression is reduced upon serum starvation 
MCF-7 cells were independently grown under various serum conditions in media containing 
foetal calf serum (FCS) or double charcoal stripped foetal calf serum (DCS FCS). Total 
protein extracts were isolated 24h following serum starvation and subjected to Western blot 
analysis with antibodies specific for AP-2γ, FOXM1 and ERα.  
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3.2.8 Effects of reduced serum concentrations on FOXM1 expression 
in AP-2γ over-expressing cells 
 
As shown in Figure 3.4A, over-expression of AP-2γ in MCF-7 cells results in an activation of 
FOXM1 at protein level while endogenous AP-2γ does not have an effect on FOXM1 
expression under starvation conditions. Therefore, a combination of the aforementioned 
conditions were performed in MCF-7 cells to further test if higher concentrations of AP-2γ 
could activate FOXM1 in a serum starved state. MCF-7 cells were transiently transfected 
with AP-2γ for 48 hours in the presence of 0.5% FCS. The transient transfection results 
showed that over-expression of AP-2γ did not change FOXM1 expression at protein and 
mRNA levels, while ERα expression were not affected (Figure 3.9). A similar experiment 
was performed in MDA-MB-231. Interestingly, western blot results showed FOXM1 
expression decreased at higher AP-2γ concentration suggesting that AP-2γ might interact 
with FOXM1 in a direct manner in MDA-MB-231 cells (Figure 3.9).  
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Figure 3.9: AP-2γ regulates FOXM1 at translational level 
MCF-7 and MDA-MB-231 cells were transiently transfected with increasing amounts (0, 1 
and 2 μg) of AP-2γ and were starved in 0.5% Foetal Calf Serum (FCS) for 24h. A, Protein 
lysates were prepared for Western blotting where specific antibodies were used to examine 
protein expression levels. B, Total RNA was isolated from MCF-7 (black bars) and MDA-
MB-231 (maroon bars) cells that were transiently transfected with AP-2γ where mRNA 
levels of AP-2γ, FOXM1 and ERα were analyzed by RT-qPCR normalized with L19 mRNA 
levels. Average of two independent experiments. Mean ± S.E.M, (* p < 0.05, *** p < 0.0001; 
two-tailed Dunnett‟s t test where 0 ng as control). 
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3.2.9 AP-2γ, FOXM1 and ERα expressions in MCF-7 cells upon 
treatment with anti-oestrogens  
 
It is still unclear whether AP-2γ directly or indirectly regulates FOXM1 expression although 
the majority of results suggest a direct interaction without the involvement of ERα. To further 
determine the role of ERα in this context, MCF-7 cells were treated with anti-oestrogens, 4-
OHT and ICI 182780 independently at various time points. It has been shown that ERα 
function is abrogated in the presence of anti-oestrogens which then inhibit oestrogen 
dependent cell growth. FOXM1 expression also decreases upon anti-oestrogen in ERα-
positive cell lines. A similar result was observed at protein level in MCF-7 cells upon 4-OHT 
and ICI 182780 treatment (Figure 3.10). Interestingly, AP-2γ expression also decreased. This 
may be due to the fact that EREs are present in the 5‟untranslated region (5‟-UTR) of AP-2γ 
where AP-2γ can be activated upon oestrogen binding (Orso, Cottone et al. 2004). These 
results suggest that ERα may play a role in the regulation of AP-2γ and FOXM1 in MCF-7 
cells. However, the down-regulation of FOXM1 can also be due to reduced AP-2γ 
expression. 
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Figure 3.10: Anti-oestrogen treatment reduces the expression of FOXM1 and AP-2γ  
MCF-7 cells were treated with anti-oestrogens, 500nM 4-OHT and 1x10
-7 
M ICI 182780. 
Protein lysates were prepared after 24h of drug treatment. The protein expression of AP-2γ, 
FOXM1 and ERα were examined by Western blot analysis using specific antibodies. 
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3.3 DISCUSSION 
 
Activator protein-2 (AP-2) transcription factors are generally known for their role in the 
regulation of normal breast development including cell proliferation, differentiation and 
apoptosis. However, aberrant activity of AP-2 has been linked with breast carcinogenesis 
(Pellikainen and Kosma 2007). Among the five members of AP-2 family, elevated levels of 
AP-2γ have been associated with adverse phenotype and increased disease progression. In 
breast cancer, high levels of AP-2γ are shown to be strongly correlated with shorter life span 
(Williams, Scibetta et al. 2009). Besides AP-2γ, other key transcription factors are also 
known to play a role in breast cancer initiation and progression such as oestrogen receptor α 
(ERα) and ErbB2. Interestingly, AP-2γ has been shown to regulate ERα by directly activating 
ERα transcription. Furthermore, AP-2γ was also found to regulate FOXM1 transcription 
factor which is a key cell-cycle regulator (Costa 2005; Li, Goswami et al. 2006; Woodfield, 
Horan et al. 2007). Recent studies have implicated AP-2γ in promoting cell proliferation 
which suggests a positive correlation with genes regulating cell cycle (Williams, Scibetta et 
al. 2009). However, limited studies have been conducted to identify the role of AP-2γ in 
regulating FOXM1 which may offer a potential candidate as therapeutic targets for breast 
cancer.  
 
In this chapter, the association between AP-2γ and FOXM1 via mediating ER signals was 
identified in breast carcinoma cell lines. As the exact function of AP-2γ in breast cancer 
development and progression has been the subject of controversy (Ailan, Xiangwen et al. 
2009), a similar concern arose in this chapter. The association between AP-2γ and FOXM1 
was first identified in a panel of breast cell lines whereby a positive association between these 
two transcription factors were apparent in MCF-7, T-47D, MDA-MB-453 and MDA-MB-468 
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cell lines. Since ERα has been shown to be involved in the regulation of AP-2γ and FOXM1 
in breast cancer, it was also interesting to discover its role in this association. Therefore, 
ERα-positive MCF-7 cells were selected to run the following experiments.  
 
AP-2γ significantly repressed FOXM1 activity in truncated promoter constructs (ApaI and 
PvuI) compared to wild-type FOXM1 promoter. ApaI promoter sequence is a GC-rich DNA 
sequence which is an important characteristic of AP-2γ binding to its target genes (Korver, 
Roose et al. 1997; Pellikainen and Kosma 2007). Repression of FOXM1 activity by AP-2γ 
contradicts with current studies which associates AP-2γ with continued cell proliferation in 
breast cancer. Hence two explanations can be given to explain this effect. It is either a true 
negative association between AP-2γ and FOXM1 or a false positive result which can appear 
due to squelching effect that inhibits gene transcription. Since ApaI confers higher activity 
compared to other tested promoter constructs and is a potential target of AP-2γ, certain 
regions were mutated in the consensus ERE ApaI (mERE) construct to identify whether ERα 
was required in the repression of FOXM1 activity by AP-2γ (Korver, Roose et al. 1997). 
Induction of mERE3 and mERE4 ApaI activity was observed upon titration of AP-2γ 
suggesting the requirement of ERα in the repression of FOXM1 activity.  
 
Overexpression of AP-2γ in MCF-7 and MDA-MB-231 presented different results on 
regulating FOXM1. When MCF-7 cells were transfected with increasing concentrations of 
AP-2γ, FOXM1 expression increased at protein level. A similar experiment was conducted in   
MDA-MB-231 cell line which expresses AP-2γ at a low level to identify whether the increase 
of FOXM1 was through ERα or independent of ERα. High levels of FOXM1 were 
maintained at protein level despite increasing AP-2γ concentrations and this could not 
determine the involvement of ERα.  Previous literature has shown that AP-2γ inhibits MDA-
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MB-231 cell growth by upregulating p21 and causing cell cycle arrest at G1/G0 phase (Li, 
Goswami et al. 2006). However, AP-2γ also stimulates cell proliferation which promotes 
tumor progression (Pellikainen and Kosma 2007). This dual role of AP-2γ probably explains 
the FOXM1 expression in MDA-MB-231 cell line. Another complementary approach was 
used to determine the regulation of FOXM1 by AP-2γ. Knockdown of AP-2γ led to down-
regulation of FOXM1 and ERα at transcriptional and translational levels. Both the over-
expression and knockdown assays suggests that FOXM1 is a down-stream target of AP-2γ in 
MCF-7 cells but it is still unclear whether ERα is involved in this regulation. To further 
clarify this doubt, AP-2γ was knocked-down in an ERα-negative cell line to look at its effect 
on FOXM1. MLET2 cells were selected among a panel of anti-oestrogen resistant cell lines 
which showed positive association between AP-2γ and FOXM1 expressions. FOXM1 
expression decreased at protein and mRNA levels upon AP-2γ gene knockdown further 
supporting the possibility of a direct association between these two transcription factors. 
Recent studies have shown that high levels of AP-2γ are associated with resistance to 
endocrine therapy (Williams, Scibetta et al. 2009). High levels of AP-2γ and FOXM1 in 
MLET‟s may contribute to its anti-oestrogen phenotype.  
 
FOXM1 is a typical proliferation-associated transcription factor. It coordinates cell growth by 
regulating genes that are involved in cell cycle. However, FOXM1 expression is induced with 
various proliferation signals such as serum, growth hormones. In the present study, MCF-7 
cells were starved at different serum concentrations to determine its effect on AP-2γ, ERα 
and FOXM1 at protein levels. As stated in the results, FOXM1 expression decreased in lower 
serum concentrations. Cells in low serum conditions enter the quiescent or resting phase of 
the cell cycle (G0) resulting in less cell proliferative activity (Wierstra and Alves 2007). This 
explains the reduced expression of FOXM1. Interestingly, ERα also showed similar 
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expression pattern but serum starvation had comparative less effect on AP-2γ. Reduced ERα 
expression at lower serum conditions suggests the importance of growth factor in influencing 
ERα activity as ERα can be activated through Activation Function-1 (AF-1) which is a non-
oestrogen-dependent domain (Badve and Nakshatri 2009). As stated in the results, over-
expression of AP-2γ led to an increase in FOXM1 expression. Since endogenous AP-2γ did 
not increase FOXM1 expression at low serum conditions, AP-2γ was over-expressed in 
MCF-7 cells starved in 0.5% Foetal Calf Serum (FCS) to identify whether it had effect on 
FOXM1 expression. No changes were observed in FOXM1 expression at transcriptional and 
translational levels suggesting that AP-2γ does not influence the regulation of FOXM1 in 
reduced serum conditions where growth factors have a greater influence. A similar 
experiment was conducted in MDA-MB-231 cells to identify whether ERα was involved in 
this association. Interestingly, FOXM1 expression decreased at protein level in over-
expressed MDA-MB-231 cells compared to control. This suggests a direct association 
between AP-2γ and FOXM1 in MDA-MB-231 cells. MDA-MB-231 is an aggressive breast 
cancer cell line which expresses high levels of FOXM1. Reduced FOXM1 expression in 
serum starved cells over-expressing AP-2γ proposes an important role of AP-2γ in inhibiting 
MDA-MB-231 cell growth. However, more detailed studies should be carried out to 
investigate this regulation.  
 
Finally, MCF-7 cells were treated with anti-oestrogens, 4-OHT and ICI 182780 to further 
understand the role of ERα in the regulation of FOXM1 by AP-2γ in breast cancer. Anti-
oestrogens inhibit transcription of oestrogen-regulated genes which prevents breast cancer 
progression. From the obtained results, both protein levels of AP-2γ and FOXM1 decreased 
after treatment with anti-oestrogen. Two possible mechanisms can be extracted from these 
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observations. Firstly, ERα might regulate FOXM1 and AP-2γ independently. Secondly, ERα 
probably regulates AP-2γ which then affects FOXM1 expression.  
 
As a whole, the majority of the results support a direct association of AP-2γ and FOXM1. 
However, these results also show that AP-2γ may not be a key regulator of FOXM1 in breast 
cancer. Since the work on AP-2γ has raised several controversies regarding its role in the 
development and progression of breast cancer, a concrete conclusion could not be achieved 
from this chapter. Nevertheless, AP-2γ could be a possible therapeutic target for breast cancer 
treatment.  
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4 CHAPTER 4: ROLE OF FORKHEAD TRANSCRIPTION 
FACTORS AND ERα IN ENDOCRINE SENSITIVE AND 
RESISTANT BREAST CANCER CELLS
90 
  
 
4.1 INTRODUCTION 
 
Forkhead box proteins (FOX) are transcription factors that play essential roles in the 
regulation of normal cell growth and development (Ma, Tong et al. 2005). As a result, 
deregulation of these Fox factors can lead to cancer initiation and progression. The role of 
FOX proteins in breast cancer development has been studied extensively over the past few 
years and various studies have shown interesting correlations of FOX proteins in breast 
tumorigenesis. Besides FOX proteins, ERα is known to play a major role in breast cancer and 
identifying its status in invasive carcinomas has become a standard practice prior to treatment 
procedures (Putti, El-Rehim et al. 2004). The relationship between FOX transcription factors 
and ERα in breast cancer has been shown recently and continuous studies are taking place to 
further validate the contribution of both transcription factors in breast cancer development. 
As FOXM1 is highly expressed in proliferating cells and a key regulator of the cell cycle 
phases, while FOXA1 and FOXC2 are expressed heterogeneously in breast cancer cells, it 
was interesting to look at the correlation among these transcription factors and ERα 
(Madureira, Varshochi et al. 2006).  
 
Endocrine resistance is common among breast cancer patients who initially respond to 
tamoxifen treatment but eventually acquire resistance which causes the disease progression 
(Dawood and Cristofanilli 2007). Although several mechanisms leading to endocrine 
resistance have been suggested and other endocrine agents were developed, it was interesting 
to identify whether Forkhead transcription factors could play a part in endocrine resistance. 
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4.2 RESULTS 
 
4.2.1 Forkhead transcription factors and ERα expression in breast 
          carcinoma cells 
 
The expression of FOXM1, FOXA1, FOXC2 and ERα in non-malignant and malignant 
human mammary cell lines were firstly determined in a panel of 14 different breast cell lines. 
Western blot results for FOXM1, ERα and β-tubulin in Figure 4.1 is used as reference to 
Figure 3.1. Western blot analysis revealed high levels of FOXM1 in almost all breast cancer 
cells except in non-tumourigenic epithelial cell line, MCF10A. This is in line with previous 
studies that showed over-expression of FOXM1 in breast cancer (Bektas, Haaf et al. 2008). 
ERα was found to be expressed in recognized ERα-positive cell lines; MCF-7, BT-474 and 
T-47D. Although ZR-75-1 and ZR-75-30 are ERα-positive, ERα was not detected in these 
cell lines. Besides FOXM1, other members of the Forkhead transcription factor family that 
were recently shown to be involved in the development of breast cancer are FOXA1 and 
FOXC2. High levels of FOXA1 were observed in HBL-100, MCF-7, ZR-75-1, ZR-75-30, 
BT-474 and T-47D cell lines which complies with studies that have reported a positive 
association between FOXA1 and ERα (Nakshatri and Badve 2009). There was a positive 
association between FOXA1 and FOXM1 expression in 4 out of 6 cell lines that expressed 
FOXA1 (HBL-100, MCF-7, ZR-75-1, ZR-75-30). FOXC2 were expressed heterogeneously 
among the cell lines (Figure 4.1). 
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Figure 4.1: Expression of Forkhead transcription factors and ERα in benign and 
malignant breast cancer cell lines 
Western blot analysis was performed using specific antibodies against FOXM1, ERα, 
FOXA1, FOXC2 and β-tubulin and their correlations were examined. β-tubulin was used as 
loading control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
93 
4.2.2 The pattern of expression for Forkhead transcription factors and  
          ERα in MCF-7 derived anti-oestrogen resistant cell lines 
  
The expression levels of FOXM1 and ERα in MCF-7 derived anti-oestrogen resistant cell 
lines has been previously described in Chapter 3 (3.2.5). Western blot results for FOXM1, 
ERα and β-tubulin in Figure 4.2 is used as reference to Figure 3.6. Protein levels of FOXA1 
and FOXC2 showed an interesting association to ERα expression at translational level when 
these resistant cell lines (MLET1, MELT2, MLET5, MCF-7/TAM
R
-4 and MCF-7/TAM
R
-7) 
were subjected to Western blotting analysis. Resistant cells that did not express ERα (MLET1 
and MLET2) or expressed ERα at lower levels (MCF-7/TAMR-4 and MCF-7/TAMR-7) 
compared to MCF-7 cells showed reduced FOXA1 expression at protein and mRNA levels. 
FOXC2 which was found to inversely correlate with FOXA1 showed a higher expression 
pattern in MLET1, MCF-7/TAM
R
-4 and MCF-7/TAM
R
-7 at translational level compared to 
MCF-7 parental cell line (Figure 4.2). These results together suggests that cells expressing 
ERα are more likely to have better prognosis as it has high levels of FOXA1 which is a good 
prognostic marker for ERα-positive breast cancers (Nakshatri and Badve 2009) and low 
levels of FOXC2 which is associated with tumour metastasis (Mani, Yang et al. 2007). 
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Figure 4.2: Expression of Forkhead transcription factors and ERα in MCF-7 derived 
resistant cell lines 
A, Western blot analysis were carried out on a panel of anti-oestrogen resistant cells lines; 
MLET1 (M1), MLET2 (M2), MLET5(M5), MCF-7/TAM
R
-4 (R4) and MCF-7/TAM
R
-7 (R7) 
which were derived from parental MCF-7 cells. β-tubulin was used as loading control. B, 
mRNA levels of FOXM1, ERα and FOXA1 were examined using RT-qPCR analysis. 
Experiments were repeated twice and represented as Mean ± S.E.M. 
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4.2.3 Knockdown of ERα results in down-regulation of Forkhead  
          transcription factors in MCF-7 cells 
 
The role of ERα in the development and progression of breast cancer has been explored 
extensively for many years. However, its role with some members of the Forkhead 
transcription factor family (FOXA1 and FOXC2) which are also known to be involved in 
breast cancer progression is still unclear. To test whether ERα regulates these transcription 
factors, ERα-positive MCF-7 cells were transfected with siRNA directed against ERα for 48 
hours. Ablation of ERα protein in MCF-7 cells resulted in reduced FOXM1 and FOXC2 
expression at translational level with no effect on FOXA1 (Figure 4.3A) which suggests 
potential down-stream targets of ERα. mRNA levels of ERα, FOXM1 and FOXA1 were 
measured by RT-qPCR. By 48 hours after transfection, FOXM1 mRNA decreased following 
elimination of endogenous ERα. In contrast to FOXA1 protein results, mRNA levels of 
FOXA1 increased compared to control (non-targeting siRNA) upon ERα knockdown 
suggesting that the FOXA1 regulation by ERα is at translational level only (Figure 4.3B).   
The relationship between ERα and FOXM1 has been previously described where FOXM1 is 
a transcriptional target of ERα (Millour, Constantinidou et al. 2010). 
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Figure 4.3: Knockdown of ERα leads to down-regulation of FOXM1 and FOXC2 at 
protein level in MCF-7 cells 
A, MCF-7 cells were transfected with mock, ERα specific siRNA (Si) and control non-
specific siRNA (NS). After 48 h transfection, protein lysates were subjected to Western 
blotting analysis. B, Quantitative real time PCR of ERα, FOXM1 and FOXA1 expressions 
was performed on reverse-transcribed RNA from MCF-7 cells. Experiments were repeated 
twice and represented as Mean ± S.E.M. Statistical analysis was done using Student‟s t test, 
(* p < 0.05, *** p < 0.001). 
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4.2.4 Knockdown of FOXA1 in MCF-7 cells down-regulates FOXM1  
          expression at protein level 
 
ERα knockdown in MCF-7 cells appear to have an effect on FOXM1 and FOXC2 (Figure 
4.3). Since the relationship between ERα and FOXM1 has been previously described 
(Millour, Constantinidou et al. 2010), it was interesting to identify the function of FOXA1 
and its association with ERα, FOXM1 and FOXC2 in breast cancer. To investigate this 
association, the effect of FOXA1 knockdown on ERα, FOXM1 and FOXC2 expression was 
determined in MCF-7 cells. Cells were transfected with FOXA1 specific siRNA, mock 
transfected and non-specific control (NS) siRNA. As shown in Figure 4.4A, the FOXA1 siRNA 
effectively knocked-down the expression of FOXA1 by 72 hours, which in turn resulted in a 
slight reduction of FOXM1 expression with no effect on ERα and FOXC2 expression 
compared to control at protein level. RT-qPCR analysis of the knock-down cells showed no 
effect on FOXM1 and ERα mRNA levels (Figure 4.4B). These results indicate that FOXA1 
may act on FOXM1 at translational level and no changes occurring at transcriptional level 
can be due to be the fact that other proliferation-associated transcription factors are regulating 
FOXM1 transcription (McGovern, Francis et al. 2009). 
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Figure 4.4: Knockdown of FOXA1 expression leads to slight reduction in FOXM1 
expression at protein level 
A, MCF-7 cells were transfected with mock, siRNA targeting FOXA1 and control non-
specific siRNA (NS). Cells lysates were prepared after 72 h transfection and the expression 
of FOXA1, FOXM1, FOXC2, ERα and β-tubulin was analyzed by Western blotting. B, Total 
RNA was extracted from MCF-7 cells and subjected to RT-qPCR analysis of relative mRNA 
levels for FOXA1, FOXM1 and ERα. Experiments were repeated twice and represented as 
Mean ± S.E.M. Statistical analysis was done using Student‟s t test, (*** p < 0.001). 
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4.2.5 Alteration of FOXA1 expression in breast carcinoma cells 
 
To further explore the possibility that FOXA1 may modulate FOXM1expression in breast 
cancer, MCF-7 cells were transiently transfected with FOXA1 expression vector for 48 hours. 
Western blot analysis confirmed the over-expression of FOXA1 (Figure 4.5). In contrast to 
the earlier experiment that showed reduction of FOXM1 expression in FOXA1 knocked-
down cells, the levels of FOXM1 remained unchanged in the FOXA1 over-expressed cells. 
This can be due to the fact that FOXM1 expression is already at its peak as MCF-7 cells are 
normal cycling cells. Alteration of the FOXA1 expression in MCF-7 cells did not influence 
ERα activity at protein and mRNA levels suggesting an unlikely regulation of ERα 
expression by FOXA1 in these cells. Figure 4.2A showed an inverse correlation between 
FOXA1 and FOXC2. MCF-7 cells either express FOXC2 at a very low level or do not 
express it all while high levels of FOXA1 are detected in this cell line. From these results, 
over-expression of FOXA1 did not stimulate FOXC2 expression at translational level 
suggesting the presence of FOXA1 might suppress the expression of FOXC2 or other 
transcription factors are influencing the stimulation of FOXC2 expression in MCF-7 cells.  
 
In order to understand the relationship between FOXA1 and FOXC2 in breast cancer cells, 
MDA-MB-231 cell line was selected to study the interaction. MDA-MB-231 cells are known 
to express high levels of FOXC2 while FOXA1 is undetected in this cell line therefore 
making it a good candidate to study the effect of FOXA1 over-expression on FOXC2 
expression. MDA-MB-231 cells were transiently transfected with FOXA1 expression vector 
and the over-expression was confirmed with Western blotting (Figure 4.5). By 48 hours 
transfection, there was a slight reduction in the protein expression of FOXC2 in FOXA1 
over-expressed cells. Interestingly, FOXM1 also decreased in protein level. These results 
together indicate that FOXA1 may play an important role in the regulation of FOXM1 and 
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FOXC2 which are expressed highly in MDA-MB-231 cell line that may also contribute to its 
aggressive phenotype. 
 
The role of FOXA1 in breast cancer cells were extended to MCF-7 derived resistant cell line, 
MLET2. The establishment of this cell line has been previously described in 3.2.5 and the 
expressions of FOXM1, FOXA1, FOXC2 and ERα has been explained in 4.2.2. FOXA1 was 
over-expressed in this cell line for 48 hours to look at its effect on FOXC2. Western blot 
analysis revealed unchanged levels of FOXC2 in cells over-expressing FOXA1. Furthermore, 
when these cells were examined for FOXM1 expression, no changes between FOXA1 control 
vector and FOXA1 expression vector were observed. From these results, FOXA1 does not 
seem to play a crucial role in regulating the expression of FOXC2 and FOXM1 where other 
factors might play a more important role in their regulations. Furthermore the resistant 
phenotype may hinder the response to the effect of FOXA1 over-expression in MLET2 cell 
line. When the over-expression results are put together, different mechanisms of FOXA1 
regulation appears to take place in the sensitive MCF-7 and resistant MDA-MB-231 and 
MLET2 cell lines. Therefore, more detailed experiments should be carried out to further 
understand the mechanisms that are occurring in these cell lines. 
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Figure 4.5: Overexpression of FOXA1 in breast carcinoma cells 
MCF-7, MDA-MB-231 and MLET2 cells were transiently transfected with FOXA1 for 48h. 
Protein lysates were prepared for Western blotting where specific antibodies were used to 
examine protein expression levels. Experiments were repeated twice. 
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4.2.6 Expression patterns of forkhead transcription factors in  
          endocrine sensitive and resistant breast cancer cells following  
          4-OHT treatment  
 
Anti-oestrogen tamoxifen is used as the first-line endocrine therapy for ER-positive breast 
cancer patients. Patients who initially respond to this treatment tend to acquire resistance over 
time hence leading to disease progression. A complete understanding of the overall 
mechanisms contributing to tamoxifen-resistant proliferation remains unexplained (Meijer, 
van Agthoven et al. 2006). To test whether Forkhead transcription factors play a role in 
mediating endocrine resistance, the effects of tamoxifen on FOXM1 expression in sensitive 
and resistant breast carcinoma cell lines were studied. The tamoxifen-sensitive cell line MCF-
7 as well as the tamoxifen-resistant MLET1, MLET2, MLET5, MCF-7/TAM
R
-4 and MCF-
7/TAM
R
-7 cells were treated with 500nM tamoxifen for 0, 8, 24, 48 and 72 hours before cells 
were collected for protein analysis at the indicated time points (Figure 4.6A) . Treatment with 
tamoxifen led to a reduction in FOXM1 protein level by 72 hours, in the sensitive MCF-7 
cells. Western blotting revealed a different expression pattern of FOXM1 in the resistant cell 
lines. Despite a small transient decline, no major decreases in FOXM1 levels were observed 
in the resistant cell lines. RT-qPCR analysis showed a reduction in FOXM1 mRNA levels in 
MCF-7 and MLET5 cell lines by 72 hours while MLET1 and MLET2 results were consistent 
with the Western blot results. Tamoxifen did not repress FOXM1 mRNA expressions in 
MCF-7/TAM
R
-4 and MCF-7/TAM
R
-7 cells (Figure 4.6B). These results together suggest that 
FOXM1 may be one of the important mediators for endocrine resistance in breast cancer 
cells. Since the presence of ERα is important for tamoxifen to inhibit oestrogen-dependent 
proliferation, the absence of this transcription factor should be the primary factor for acquired 
resistance. However, loss of ERα expression only occurs in a small percentage (15-20%) of 
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resistant breast cancers suggesting that the absence of ERα is not the major contributing 
factor to endocrine resistance. As explained in 3.2.5, resistant cells MLET1 and MLET2 lost 
their ERα expression while MLET5, MCF-7/TAMR-4 and MCF-7/TAMR-7 cells expresses 
ERα which further supports the previous findings of ERα and endocrine resistance 
(Musgrove and Sutherland 2009). 
 
Besides studying the expression pattern of FOXM1 in tamoxifen treated sensitive and 
resistant cell lines, it was also interesting to look at the effects of this treatment on the 
recently discovered FOXA1 transcription factor in breast cancer. Western blot analysis 
revealed a time-dependent induction of FOXA1 activity in MCF-7, MLET5, MCF-7/TAM
R
-4 
and MCF-7/TAM
R
-7 cells. The expression levels of FOXA1 were undetected in MLET1 and 
MLET2 cell lines which further support the regulation of FOXA1 by ERα (Figure 4.6A). RT-
qPCR was performed to investigate whether FOXA1 was up-regulated by tamoxifen at 
transcriptional level (Figure 4.6C). The RT-qPCR analysis showed that FOXA1 transcripts 
increased with time in MCF-7 and MLET5 cells while the opposite effects were observed in 
MCF-7/TAM
R
-4 and MCF-7/TAM
R
-7 cells. No major changes were observed in MLET1 and 
MLET2 cells. Theoretically, down-regulation in FOXA1 expression were expected to be seen 
in tamoxifen treated MCF-7 cells. This is because the activity of ERα is inhibited in sensitive 
MCF-7 cells upon tamoxifen binding which should also lead to a decrease in FOXA1 activity 
as FOXA1 is a direct target of ERα. The results obtained in MCF-7 cells at protein and 
mRNA levels suggest that either tamoxifen stabilizes ERα which induces FOXA1 expression 
or other mechanisms are involved that contributes to the FOXA1 up-regulation in MCF-7 
cells. The increase in FOXA1 expressions at translational levels in the MLET5, MCF-
7/TAM
R
-4 and MCF-7/TAM
R
-7 resistant cells further shows that ERα is essential for 
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FOXA1 regulation. Collectively, these results indicate that FOXA1 is not involved in the 
development of endocrine resistance. 
 
Another Forkhead transcription factor that has been recently discovered to be involved in the 
progression of breast cancer is FOXC2. However, a well-defined role of FOXC2 in the 
development of breast cancer has not been established. A heterogeneous expression pattern of 
FOXC2 was observed in tamoxifen treated sensitive and resistant cell lines (Figure 4.6A). As 
FOXC2 is either undetected or expressed at a very low level in MCF-7 cells, the effects of 
tamoxifen on FOXC2 expression was not apparent at protein level. No changes in FOXC2 
expression was observed in MLET1, MLET2 and MLET5 cells. Interestingly, treatment with 
tamoxifen led to an increase in FOXC2 protein levels by 24 hours in MCF-7/TAM
R
-4 and 
MCF-7/TAM
R
-7. Taken together, these results suggest that ERα does not seem to influence 
FOXC2 activity in MCF-7, MLET1, MLET2 and MLET5. Nevertheless, the up-regulation of 
FOXC2 in MCF-7/TAM
R
-4 and MCF-7/TAM
R
-7 may likely to contribute to the resistance in 
these cell lines which can also lead to tumour invasion and metastasis as FOXC2 is found to 
be overexpressed in metastatic cancers (Mani, Yang et al. 2007). 
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Figure 4.6a: Effect of tamoxifen on expression of Forkhead transcription factors and ERα in a panel of MCF-7 sensitive and resistant 
cells at translational levels 
MCF-7, MLET1, MLET2, MLET5, MCF-7/TAM
R
-4 and MCF-7/TAM
R
-7 cells were treated with 500nM of tamoxifen for 0, 8, 24, 48 and 72h. 
Protein lysates were prepared and protein expression levels were analyzed by Western blotting using specific antibodies. β-tubulin was used as 
loading control. 
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Figure 4.6b: Effect of tamoxifen on expression of FOXM1 in MCF-7 sensitive and 
resistant cells at transcriptional levels 
MCF-7, MLET1, MLET2, MLET5, MCF-7/TAM
R
-4 and MCF-7/TAM
R
-7 cells were treated 
with 500nM of tamoxifen for indicated time points before cells were collected and total RNA 
was extracted. FOXM1 mRNA levels were analyzed with real-time quantitative PCR 
normalized with L19 mRNA levels. Experiments were done in triplicate. Mean ± S.D.  
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Figure 4.6c: Effect of tamoxifen on expression of FOXA1 in MCF-7 sensitive and 
resistant cells at transcriptional levels 
MCF-7, MLET1, MLET2, MLET5, MCF-7/TAM
R
-4 and MCF-7/TAM
R
-7 cells were treated 
with 500nM of tamoxifen for indicated time points before cells were collected and total RNA 
was extracted. FOXA1 mRNA levels were analyzed with real-time quantitative PCR 
normalized with L19 mRNA levels. Experiments were done in triplicate. Mean ± S.D.  
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4.2.7 Expression patterns of forkhead transcription factors in  
          endocrine sensitive and resistant breast cancer cells following 
          ICI 182780 treatment  
 
As the first-line of hormonal therapy has been associated with endocrine resistance, it was 
essential to find an alternative treatment that would overcome this resistance. Hence, a „pure‟ 
anti-oestrogen with potential therapeutic benefits over tamoxifen was developed (Howell, 
Johnston et al. 2004). To further asses the relationship between Forkhead transcription factors 
and endocrine resistance, MCF-7, MLET1, MLET2, MLET5, MCF-7/TAM
R
-4 and MCF-
7/TAM
R
-7 were treated with 1x10
-7 
M of ICI 182780 over a time course lasting 72 hours. The 
expression levels of FOXM1 and ERα were analyzed by Western blotting. As shown in 
Figure 4.7A, protein levels of ERα decreased by 8 hours following ICI 182780 treatment. 
This is in concordance with ICI 182780‟s characteristic as a selective oestrogen receptor 
down-regulator (SERD) where it causes rapid ERα degradation. Expression levels of FOXM1 
declined 24 hours after ICI 182780 treatment in MCF-7 and MCF-7/TAM
R
-4. Despite a 
transient decline at 24 and 48 hours, no major decreases in FOXM1 levels were observed in 
the MLET5 cells. High levels of FOXM1 were maintained in MLET1, MLET2 and MCF-
7/TAM
R
-7 upon ICI 182780 treatment at translational levels. The RT-qPCR analysis showed 
that the abundance of FOXM1 transcripts decreased by 72 hours of ICI 182780 treatments in 
MCF-7, MLET1, MLET2, MLET5 and MCF-7/TAM
R
-4. Consistent with western blotting 
results, ICI 182780 did not repress FOXM1 mRNA expressions in MCF-7/TAM
R
-7 cells 
(Figure 4.7B). Pure anti-oestrogen ICI 182780 clearly had an effect on FOXM1 activity 
through down-regulation of ERα in MCF-7 sensitive cells. Although MCF-7/TAMR-4 is 
resistant to tamoxifen, the presence of ERα allowed the response to second-line treatment 
which led to a reduction in FOXM1 levels. MLET5 cell line that expresses ERα is partially 
sensitive to anti-oestrogen which explains the reduction of FOXM1 expression levels. 
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FOXM1 activity was not affected by ICI 182780 treatment in MLET1 and MLET2 cell lines 
at protein levels which shows the importance of ERα in the mechanism of action of ICI 
182780. However, FOXM1 mRNA levels declined by 72 hours suggesting other mechanisms 
might be involved in its regulation at transcriptional levels. No changes observed in the 
FOXM1 expression at protein and mRNA levels in MCF-7/TAM
R
-7 although ERα is present 
suggest FOXM1 mediates resistance in this cell line. 
 
The expression levels of FOXA1 were also studied in these cell lines (Figure 4.7A). ICI 
182780 repressed FOXA1 expression in MCF-7 cells by 8 hours of treatment while high 
levels of FOXA1 were maintained in MLET5 and MCF-7/TAM
R
-4 cells at protein levels. An 
induction of FOXA1 activity was observed in MCF-7/TAM
R
-7. However, Western blotting 
showed undetected levels of FOXA1 in MLET1 and MLET2 cells. RT-qPCR analysis was 
performed on the sensitive and resistant cell lines to examine the FOXA1 activity following 
ICI 182780 treatment (Figure 4.7C). ICI 182780 showed no effect on the mRNA expression 
of FOXA1 in all the cell lines. The down-regulation of FOXA1 following ERα degradation in 
MCF-7 cells proves that ERα is an important factor in its regulation. In contrast to MCF-7, 
high levels of FOXA1 that were detected in the resistant cell lines (MLET5, MCF-7/TAM
R
-4 
and MCF-7/TAM
R
-7) despite decreasing levels of ERα suggest that other factors besides ERα 
are regulating FOXA1.  
 
FOXC2 protein levels in sensitive and resistant cells following ICI 182780 treatment were 
found to be similar to the tamoxifen treated cells. Higher levels of FOXC2 were detected in 
resistant cell lines compared to MCF-7. These results suggest FOXC2 may play a role in 
endocrine resistance.  
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Figure 4.7a: Effect of ICI on expression of Forkhead transcription factors and ERα in a panel of MCF-7 sensitive and resistant cells at 
translational levels 
MCF-7, MLET1, MLET2, MLET5, MCF-7/TAM
R
-4 and MCF-7/TAM
R
-7 cells were treated with 1x10
-7
 of ICI for 0, 8, 24, 48 and 72h. Protein 
lysates were prepared and protein expression levels were analyzed by Western blotting using specific antibodies. β-tubulin was used as loading 
control. 
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Figure 4.7b: Effect of ICI on expression of FOXM1 in MCF-7 sensitive and resistant 
cells at transcriptional levels 
MCF-7, MLET1, MLET2, MLET5, MCF-7/TAM
R
-4 and MCF-7/TAM
R
-7 cells were treated 
with 1x10
-7
 of ICI for indicated time points before cells were collected and total RNA was 
extracted. FOXM1 mRNA levels were analyzed with real-time quantitative PCR normalized 
with L19 mRNA levels. Experiments were done in triplicate. Mean ± S.D.  
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Figure 4.7c: Effect of ICI on expression of FOXA1 in MCF-7 sensitive and resistant 
cells at transcriptional levels 
MCF-7, MLET1, MLET2, MLET5, MCF-7/TAM
R
-4 and MCF-7/TAM
R
-7 cells were treated 
with 1x10
-7
 of ICI for indicated time points before cells were collected and total RNA was 
extracted. FOXA1 mRNA levels were analyzed with real-time quantitative PCR normalized 
with L19 mRNA levels. Experiments were done in triplicate. Mean ± S.D.  
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4.3 DISCUSSION 
 
Transcription factors are recognized as one of the most diverse classes of DNA-binding 
proteins that regulate gene expression in eukaryotic cells (Korver, Roose et al. 1997). 
Forkhead box proteins (FOX) belong to a family of transcription factors that are 
characterized by a 100-amino acid winged helix DNA binding domain (Kaestner, Knöchel et 
al. 2000). FOX proteins are widely known for their role in regulating cell proliferation and 
differentiation (Teh, Wong et al. 2002). However, aberrant changes in FOX function can alter 
cell fate which may lead to tumorigenesis (Myatt and Lam 2007). Several FOX proteins have 
been found to play a role in cancer aetiology (Hannenhalli and Kaestner 2009). FOXM1 is 
highly expressed in human carcinomas such as breast, prostate, brain, and lung and is 
associated with cell cycle progression. One of the FOX family members that were recently 
identified to be involved in breast cancer metastasis and invasion is FOXC2 (Myatt and Lam 
2007). FOXA1 expression is found to be correlated with luminal subtype of breast cancers 
which are good prognosis tumors (Thorat, Marchio et al. 2008). Besides the FOX family, 
another transcription factor that has significantly marked its existence in breast cancer is 
ERα. The expression of ERα in breast cancer is an essential prognosis and a predictive 
marker to endocrine therapies. Many studies have shown positive correlations between ERα 
and the FOX proteins. However continuous effort is taking place to further understand these 
relationships. 
 
The work in this chapter focuses on the relationship among FOX factors and ERα in 
endocrine sensitive and resistant breast cancer cells. The expression of various FOX proteins 
and ERα were firstly analyzed in a panel of non-malignant and malignant human mammary 
cell lines. Consistent with previous findings, FOXM1 was up-regulated in almost all the 
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breast cancer cell lines (Petrovic, Costa et al. 2008). FOXA1 was expressed in cells 
expressing ERα. This is in line with studies that showed an association between FOXA1 
expression and ERα-positivity (Thorat, Marchio et al. 2008). FOXC2 was expressed 
heterogeneously among the cell lines. From the cell panel, an interesting association was 
observed among the tested transcription factors in MCF-7 cells. This cell line was selected to 
run most of the experiments in order to explore the relationship among FOX factors and ERα. 
The expressions of FOXM1, FOXA1, FOXC2 and ERα were also studied in a panel of MCF-
7 derived anti-oestrogen resistant cell lines. MLET1 and MLET2 which are ERα-negative 
cell lines expressed higher levels of FOXC2 and lower levels of FOXA1 compared to MCF-7 
cells. A similar pattern was also observed in MCF-7/TAM
R
-4 and MCF-7/TAM
R
-7 that 
expressed lower levels of ERα compared to parental cell line. FOXM1 was expressed 
heterogeneously among the resistant cell lines. Collectively, different expression levels of the 
tested transcription factors in sensitive and resistant cells suggest that they may contribute to 
endocrine resistance. Therefore, experiments were conducted to further understand the role of 
transcription factors and ERα in breast cancer progression and whether they form a network 
of interaction or work independently.  
 
An interesting relationship was observed among the FOX factors and ERα in MCF-7 cells. 
When ERα was silenced in MCF-7 cells, the expressions of FOXM1, FOXA1 and FOXC2 
decreased at protein level. FOXM1 mRNA also showed a similar result suggesting a positive 
association between ERα and FOXM1. This relationship was previously described by 
(Millour, Constantinidou et al. 2010) that demonstrated FOXM1 as a downstream target of 
ERα. In contrast to protein level, FOXA1 mRNA increased significantly following ERα 
knockdown. In general, the amount of protein synthesized within a cell depends on the 
changes of the amount of mRNA. However, the protein levels can differ from the mRNA 
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levels in a cell based on several plausible mechanisms. Differing levels of FOXA1 can be due 
to changes in the rate of FOXA1 protein degradation and numerous post-transcriptional sites 
which could be of target to such regulation. Besides that, the changes in the amount of 
mRNA that is available for translation can be influenced by transferring the mRNA from a 
pool of polysome-associated mRNA to a pool of sequestered non-translatable mRNA (Eskild, 
Troen et al. 2000) which may lead to reduced protein synthesis.  Reduction of FOXA1 
expression in the absence of ERα further supports previous finding that identified FOXA1 as 
a direct target of ERα (Laganière, Deblois et al. 2005). 
 
Besides analyzing the importance of ERα in regulating other FOX factors in breast cancer, it 
was also interesting to look at the function of FOXA1 in relation to ERα, FOXM1 and 
FOXC2. FOXA1 is a unique member of the „winged helix‟ family as it is able to bind to 
compact DNA. Its ability to open the chromatin for binding of other transcription factors to 
its target genes makes it the „pioneer factor‟. Ablation of FOXA1 expression in MCF-7 cells 
led to a slight decrease in FOXM1 expression at translational level with no changes at 
transcriptional level. In contrast, over-expression of FOXA1 did not lead to an up-regulation 
of FOXM1 protein expression suggesting that FOXA1 may not be the key regulator of 
FOXM1. ERα expression was also not affected by knocking down and over-expressing 
FOXA1 in MCF-7 cells. FOXA1 enhances the binding of ERα to 50% of ERα regulated 
genes which contains FOXA1-binding sites (Nakshatri and Badve 2007; Badve and Nakshatri 
2009). Previous studies have shown that depletion of FOXA1 suppressed the binding of ERα 
to TFF1 promoter (which contains a FOXA1-binding site), reduced the induction of TFF1 
expression by oestradiol (E2) and prevented E2 induced re-entry into cell cycle (Laganière, 
Deblois et al. 2005). This probably explains the slight reduction in FOXM1 expression and 
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the unchanged ERα levels following FOXA1 knockdown in MCF-7 cells as the effects are 
apparent on ERα targeted genes.  
 
FOXC2, a member of the FOX family, was recently found to play a crucial role in breast 
cancer metastasis and invasion (Myatt and Lam 2007). High levels of FOXA1 inversely 
correlated with very low or undetected levels of FOXC2 in non-metastatic ERα-positive 
MCF-7 cells. This supports previous findings that showed FOXA1 expression is associated 
with the presence of ERα while FOXC2 expression correlates with tumour metastasis 
(Laganière, Deblois et al. 2005; Mani, Yang et al. 2007). The relationship between these two 
transcription factors were analysed by knocking down FOXA1 in MCF-7 cells and transiently 
transfecting FOXA1 in MCF-7, MDA-MB-231 and MLET2 cells to look at the effects of 
FOXA1 on FOXC2. Ablation and over-expression of FOXA1 did not have any effect on 
FOXC2 in MCF-7 cells. This is probably because MCF-7 is a non-metastatic cell line 
therefore; an increase or decrease in FOXA1 may not influence FOXC2 expression. Another 
possible factor could be either FOXA1 or other transcription factors might be suppressing 
FOXC2 expression. FOXC2 expressing MDA-MB-231 which is a metastatic cell line was 
selected to further study the interactions. Over-expression of FOXA1 reduced FOXC2 and 
FOXM1 expressions. This indicates that FOXA1 may play a role in suppressing both FOXC2 
and FOXM1 which may be causative factors to MDA-MB-2321 cells aggressive phenotype. 
The same expression pattern was expected in MLET2 cells over-expressing FOXA1 but no 
changes were observed in FOXC2 and FOXM1 expressions suggesting that other factors may 
regulate these transcription factors in this cell line. Although different mechanisms are taking 
place in each cell line, understanding each role of FOX proteins and its contribution in the 
development and progression of breast cancer is vital to identify potential therapeutic targets.     
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Endocrine therapy has long been an effective means of treatment to breast cancer patients 
expressing ERα. Anti-oestrogen tamoxifen is the most commonly used and tested drug in 
breast cancer. However, patients benefiting from this therapy eventually develop resistance to 
tamoxifen (Howell, Johnston et al. 2004). To tackle this phenomenon, a novel ERα antagonist 
(Fulvestrant or ICI) and aromatase inhibitors with enhanced anti-tumour effects were 
developed (Zilli, Grassadonia et al. 2009). Although several mechanisms are responsible for 
endocrine resistance, the role of FOX proteins has not been explored in the development of 
resistance.   
 
As tamoxifen acts by binding to ERα and inhibiting the proliferation of breast epithelial cells, 
FOXM1 showed an expected decrease in its expression with time in sensitive MCF-7 cells. 
This further supports the function of FOXM1 in regulating cell proliferation. However, the 
resistant cell lines did not show a decrease in FOXM1 expression despite a small transient 
decline. When the same cell lines were treated with „pure‟ anti-oestrogen, ICI 182780, 
FOXM1 levels in MCF-7 cells declined. Although FOXM1 mRNA decreased with time in 
MLET1, MLET2 and MLET5, protein levels did not show the same expression pattern. 
Tamoxifen that did not have an effect on FOXM1 levels in MCF-7/TAM
R
-4 cells, showed a 
reduction of FOXM1 expression at protein and transcriptional levels upon ICI 182780 
treatment. In contrast, no changes were of FOXM1 levels were observed in ICI 182780-
treated MCF-7/TAM
R
-7 which was also shown in tamoxifen-treated MCF-7/TAM
R
-7 cells. 
Since the presence of ERα is an important predictor to tamoxifen responsiveness, the loss of 
ERα expression might be one of the causative factors in acquiring tamoxifen resistance. 
However, ERα loss occurs only in 20% of the cases (Sommer and Fuqua 2001). Therefore, 
other major causative factors are involved in the resistance. In general, anti-oestrogen 
treatment causes cell-cycle arrest at G1 leading to a reduction in growth rate. Therefore, 
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deregulation of several down-stream targets of oestrogen and anti-oestrogen confers 
resistance, which may be linked to decrease in tamoxifen sensitivity in patients (Musgrove 
and Sutherland 2009). The Raf/MEK/MAPK pathway is shown to be important in stimulating 
nuclear translocation and transactivating activity of FOXM1 (Ma, Tong et al. 2005). Up-
regulation of receptor tyrosine kinase signalling pathways has been associated with endocrine 
resistance (Musgrove and Sutherland 2009). Therefore there are possibilities that high levels 
of FOXM1 in the resistant cell lines can be due to over-expression of the Raf/MEK/MAPK 
pathway. Collectively, FOXM1 may be an important mediator for endocrine resistance.  
 
The recently discovered FOXA1 showed an interesting expression pattern which associates it 
to being a potential therapeutic target. When MCF-7 cells were treated with tamoxifen, 
FOXA1 levels increased at protein and transcriptional levels while opposite effects were 
observed in MCF-7 cells treated with ICI 182780. FOXA1 was undetected in MLET1 and 
MLET2 cells at protein levels with very low levels of mRNA expressions in both treatments. 
High levels of FOXA1 were detected in MLET5, MCF-7/TAM
R
-4 and MCF-7/TAM
R
-7 cells 
treated independently with tamoxifen and ICI 182780at protein levels. As FOXA1 expression 
is associated with ERα positivity, cells resistant to tamoxifen have functional ERα hence 
leading to FOXA1 activation. The absence of ERα explains the undetectable levels of 
FOXA1 in MLET1 and MLET2 which further supports the established regulation of FOXA1 
by ERα. However, ICI 182780 treated resistant cells; down-regulation of FOXA1 is expected 
as ERα is degraded upon this treatment. But, high levels of FOXA1 suggest other unknown 
mechanisms are involved in its regulation. From the above results, high levels of FOXA1 
expression is correlated with good prognosis therefore this transcription factor may not be 
involved in mediating endocrine resistance (Nakshatri and Badve 2007). 
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An induction of FOXC2 expression was observed in the tamoxifen and ICI 182780 treated- 
MCF-7/TAM
R
-4 and MCF-7/TAM
R
-7 cells while no changes in the FOXC2 levels were seen 
in MLET1, MLET2, MLET5 cells. Resistant cells which had higher levels of FOXC2 than 
sensitive MCF-7 cells suggests that FOXC2 might be one of the important mediators in 
endocrine resistance as it is associated with aggressive type phenotype. Nevertheless, more 
detailed studies should be carried out to further understand its role in endocrine resistance. 
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5.1 OVERVIEW 
 
Breast cancer is the most common cause of malignancy in women worldwide. It is diagnosed 
as the second leading cancer after lung cancer (Sommer and Fuqua 2001; McGovern, Francis 
et al. 2009). The steroid hormone 17 β-oestradiol (E2) is important for the normal female 
physiology in developing and maintaining hormone-dependent reproductive tissues through 
cell proliferation and cell survival (Petz, Ziegler et al. 2004; Musgrove and Sutherland 2009). 
It has been established that prolonged exposure to E2 is associated with breast cancer 
pathogenesis as it has mitogenic effects on breast epithelial cells (Ghosh, Thompson et al. 
2000). The effects of E2 are mediated mainly through a member of the superfamily of nuclear 
receptors, oestrogen receptor α (ERα) (Laganière, Deblois et al. 2005). Approximately 60-
65% of primary breast cancers are classified as ERα-positive breast cancers (Putti, El-Rehim 
et al. 2004). Therefore, the presence of ERα is an important prognostic and predictive clinical 
marker for breast tumours responding to anti-oestrogen therapies (Sommer and Fuqua 2001). 
 
AP-2γ is one of the five members of AP-2 family of transcription factors that is required for 
early post-implantation development. AP-2 proteins also play a vital role in the normal breast 
development. However, various studies have shown the involvement of AP-2γ in breast 
cancer development where transcriptional targets include ERBB2 and ERα, both of which 
contain AP-2γ binding sequence in their promoter regions. In contrast, AP-2γ also activates 
p21
WAF1/CIP1 
and
 
inhibits cell growth of human breast carcinomas. These data altogether 
suggests a dual role for AP-2γ in tumour development and progression (Ailan, Xiangwen et 
al. 2009; Gee, Eloranta et al. 2009). Recent studies have shown an association between AP-2γ 
and continued cell proliferation, disease progression and endocrine resistance (Williams, 
Scibetta et al. 2009). 
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One of the main aims of this project was to determine the role of AP-2γ in regulating 
proliferation-associated transcription factor, FOXM1 in breast cancer and whether ERα acts 
as a mediator. The work explored the hypothesis that AP-2γ regulates FOXM1 expression in 
breast cancer. 
 
In chapter 3, a positive association between AP-2γ, FOXM1 and ERα were observed in 
MCF-7 cell line. Promoter assays revealed repression of FOXM1 activity by AP-2γ in 
truncated ApaI and PvuI promoter constructs compared to wild-type FOXM1 promoter. In 
contrast, there was an induction of FOXM1 activity in mutant ERE ApaI promoters (mERE3 
and mERE4). These results altogether suggest that the repression of FOXM1 activity in ApaI 
and PvuI promoters is through ERα. Over-expression of AP-2γ in MCF-7 cells increased 
FOXM1 expression at protein level which contradicts to the promoter assay results. When a 
similar experiment was conducted in MDA-MB-231 cells, high levels of FOXM1 were 
maintained in cells over-expressing AP-2γ. This could not determine whether the increase in 
FOXM1 in MCF-7 cells was through ERα or independent of ERα. However, a clearer 
understanding in the regulation of FOXM1 by AP-2γ in the presence or absence of ERα was 
achieved from the AP-2γ knockdown assays. Down-regulation of FOXM1 and ERα 
expressions were observed at protein and mRNA levels in MCF-7 cells following AP-2γ 
knock-down. This is in line with previous studies that showed endogenous AP-2γ regulates 
ERα in MCF-7 cells (Woodfield, Horan et al. 2007). The following experiment involved 
knockdown of AP-2γ in MLET2 cells, which led to a reduction of FOXM1 expression at 
transcriptional and translational levels. From this, the results somehow suggest that there 
might be a direct regulation of AP-2γ on FOXM1 expression MCF-7 cells. MLET2 is an anti-
oestrogen resistant cell line. Recent studies have showed that high levels of AP-2γ were 
associated with reduced response to hormone therapy (Williams, Scibetta et al. 2009). 
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Therefore, it might be possible that high levels of AP-2γ and FOXM1 that are expressed in 
this cell line can be a contributing factor to endocrine resistance. In normal cycling cells, 
FOXM1 expression is induced during G1 phase and its expression is maintained throughout S 
phase and M phase. Proliferation signals such as serum increases FOXM1 expression and its 
activity. Therefore, by reducing serum concentrations, the opposite effects are expected. In 
this chapter, MCF-7 cells were serum starved at various concentrations to determine whether 
endogenous AP-2γ could activate FOXM1 in low serum starved cells. From the results, 
endogenous AP-2γ did not have an effect on reduced FOXM1 expression upon serum 
starvation. Since over-expression of AP-2γ led to an increase in FOXM1 expression, AP-2γ 
was over-expressed in MCF-7 cells starved in 0.5% FCS to see whether it had the same effect 
on FOXM1. In contrast, AP-2γ did not increase FOXM1 expression suggesting it does not 
play a role in FOXM1 regulation under reduced serum conditions. Previous studies have 
shown that FOXM1 expression is strongly induced upon serum stimulation (Wierstra and 
Alves 2007). This suggests that proliferation signals such as serum, growth hormones play a 
significant role in regulating FOXM1 expression. Interestingly, when AP-2γ was over-
expressed in MDA-MB-231 cells starved in 0.5% FCS, FOXM1 levels decreased at protein 
level suggesting that a whole different mechanism is taking place in this cell line. However, 
more studies should be conducted to further understand the role of AP-2γ in MDA-MB-231. 
Finally, MCF-7 cells were treated with anti-oestrogens to further understand FOXM1 
regulation by AP-2γ in the presence of absence of ERα. Tamoxifen inhibits oestrogen-
dependent growth by binding to ERα while ICI 182780 causes ERα degradation (Howell, 
Johnston et al. 2004; Fan, Rickert et al. 2007). AP-2γ and FOXM1 expressions decreased 
with time suggesting that both transcription factors are down-stream targets of ERα or 
another network of ERα-AP-2γ-FOXM1 relationship could be extracted. The results in this 
chapter suggest a direct association of AP-2γ and FOXM1. However, it also shows that AP-
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2γ may not be a key regulator of FOXM1 in breast cancer. The research on AP-2γ has raised 
many controversies regarding its dual role in breast cancer development and progression.  
 
Although the work in this chapter shows an association between AP-2γ and FOXM1, more 
studies should be conducted in vivo and in vitro. Recent research has shown that AP-2γ can 
be one of the potential targets for cancer treatment. Increasing evidence reveals positive 
association between AP-2γ and transcriptional targets such ERBB2 and ERα, which are 
widely known for their involvement breast cancer development and progression (Gee, 
Eloranta et al. 2009). Furthermore high levels of AP-2γ have been linked to endocrine 
resistance (Williams, Scibetta et al. 2009). In this work, majority of the results support a 
direct association between AP-2γ and FOXM1 although it shows that AP-2γ may not be a 
key regulator of FOXM1. However, drugs can be designed to target AP-2γ which in turn will 
impede the activity of its downstream targets or indirect targets. As a result, this might slow 
down the progression of breast cancer, thus leading to increase in survival rate.  
 
Endocrine therapy is aimed at ERα-expressing tumours. Anti-oestrogen tamoxifen has been 
the first-line of endocrine treatment for ERα-positive breast cancer patients. However, 
approximately 40% of patients initially responding to this treatment die from relapse of 
disease (Normanno, Di Maio et al. 2005). In vitro and in vivo studies have shown that 
tamoxifen-resistant cell lines and tumours are responsive to growth inhibition by „pure‟ ERα 
antagonist, ICI 182780 (Fulvestrant) (Howell, Johnston et al. 2004). Endocrine resistance 
may account up to one-quarter in of all breast cancers. The effectiveness of hormonal therapy 
is challenged with the development of this resistance. To date, many mechanisms that are 
responsible for endocrine resistance have been identified. However, continuous research is 
taking place to further identify specific genetic events that cause resistance. 
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The other main aim of this thesis was to determine the role of Forkhead box proteins in 
endocrine sensitive and resistant breast cancer. The work explored the hypothesis that 
deregulation of Fox factors will overcome the dependency of breast cancer on oestradiol for 
cell growth and survival. 
 
In chapter 4, ERα-positive MCF-7 cells expressed high levels of FOXM1, FOXA1 and low 
levels of FOXC2. The relationship between these transcription factors and breast cancer were 
further assessed by silencing ERα, FOXA1 in MCF-7 and over-expressing FOXA1 in MCF-
7, MDA-MB-231 and MLET2 cell lines. Since high levels of FOXM1 and FOXC2 are 
associated with breast cancer progression, it would be an ideal approach to help prevent the 
progression by identifying potential up-stream targets of these genes that can influence their 
activity directly. Protein levels of FOXM1, FOXA1 and FOXC2 decreased following ERα 
knockdown in MCF-7 cells suggesting possible target genes of ERα in this cell line. There 
was a slight decrease in FOXM1 expression at translational level with no changes in ERα and 
FOXC2 expressions following FOXA1 knockdown in MCF-7 cells. On the other hand, over-
expression of FOXA1 did not affect FOXM1, ERα and FOXC2 expressions at translational 
levels suggesting that FOXA1 may not be the key regulator of these transcription factors. 
However, the presence of FOXA1-binding sites in 50% of ERα-regulated genes enhances the 
recruitment of ERα to its target genes (Habashy, Powe et al. 2008). Therefore, the presence or 
absence of FOXA1 may be the deciding factor in controlling the expressions of oestrogen-
responsive genes despite having similar levels of ERα, which explains the obtained results 
(Badve and Nakshatri 2009). High levels of FOXM1 and FOXC2 that are expressed in MDA-
MB-231 cells may be a contributing factor to its aggressive phenotype; hence it is important 
to target these factors. Over-expression of FOXA1 in MDA-MB-231 cells led to a reduction 
in FOXM1 and FOXC2 expressions which suggests the importance of FOXA1 in suppressing 
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the expression of both these transcription factors. A similar experiment was conducted in 
MLET2 cells which expressed low levels of FOXA1 and high levels of FOXM1 and FOXC2. 
Over-expression of FOXA1 did not influence FOXM1 and FOXC2 expressions as it did in 
MDA-MB-231 cells suggesting that other mechanisms are involved in their regulations. High 
levels of FOXM1 and FOXC2 that were detected in most of tamoxifen and ICI 182780-
treated resistant cell lines suggests FOXM1 as proliferation associated transcription factor 
and FOXC2, which is linked to tumour progression might mediate endocrine resistance in 
breast cancer. However, high levels of FOXA1 protein expressions were observed upon 
tamoxifen and ICI 182780 treatments respectively in MLET5, MCF-7/TAM
R
-4 and MCF-
7/TAM
R
-7 cell lines. Since FOXA1 is associated with good prognosis, hence high levels of 
this transcription factor may not contribute to endocrine resistance. The presence or absence 
of ERα also plays a role in resistance to endocrine therapy and this may influence the 
expressions of the aforementioned FOX transcription factors in the tested breast cancer cells.  
 
As a whole, each FOX transcription factor seems to play a vital role in breast cancer 
development and progression. High levels of FOXM1 and FOXC2 were detected in most 
anti-oestrogen resistant cell lines suggesting its contribution to endocrine resistance. 
Targeting these transcription factors might help combat endocrine resistance. In contrast, 
FOXA1 which is associated with better prognosis was expressed at higher levels in those cell 
lines. Therefore, it is vital to maintain the FOXA1 expression as one of the measures to 
facilitate the delay of breast cancer progression and resistance.  
 
Collectively, the findings suggest the importance of AP-2γ in breast cancer diagnosis. It also 
shows that FOX transcription factors could be used as prognostic markers for breast cancer 
patients, and diagnostic markers for endocrine sensitivity. In addition, high levels of AP-2γ, 
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FOXM1 and FOXC2 in most anti-oestrogen resistant cells lines suggest possible targets to 
overcome endocrine resistance. Previous studies have shown that FOXM1 is a target of 
thiazole antibiotic drug, thiostrepton (Kwok, Myatt et al. 2008). Therefore, drugs like 
thiostrepton can be used to inhibit FOXM1 activity. Despite the experiments conducted in 
this work, more in vitro experiments should be carried out for a clearer understanding of the 
mechanisms involved in breast cancer. These results should then be finally validated in 
patients‟ sample. 
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6.1 FUTURE WORK 
 
 
The work in this project suggests a direct association of AP-2γ and FOXM1 in MCF-7 cells. 
To further confirm the findings in chapter 3, chromatin immunoprecipitation (ChIP) assay 
should be done in MCF-7 cells to identify whether AP-2γ binding sites are present in the 
FOXM1 DNA sequence. ChIP technique is used to identify binding sites of transcription 
factors on the genome of a particular protein of interest (Ailan, Xiangwen et al. 2009). To 
investigate whether ERα is involved in the interaction between AP-2γ and FOXM1 in MCF-7 
cells, ERα should be knocked down by siRNA followed by ChIP to determine whether AP-2γ 
binds directly on FOXM1 or via ERα. To further validate the findings, ChIP could also be 
done in ERα-negative cell lines which express high levels of AP-2γ and FOXM1 such as 
MDA-MB-453 cell line. FOXM1 expression peaks at G2/M phase which defines its role as 
cell cycle regulator (Bektas, Haaf et al. 2008). Therefore, it would be interesting to look at the 
cell cycle profile in MCF-7 and MDA-MB-453 cell lines following AP-2γ knock-down. The 
cell cycle analysis will show whether FOXM1 is affected upon AP-2γ knock-down and 
whether the effect is through ERα or independent of ERα by comparing the results in ERα-
positive and ERα-negative cell lines. High levels of AP-2γ expression has been recently 
shown to be associated with failure in endocrine therapy and reduced survival rates 
(Williams, Scibetta et al. 2009). Therefore, it would be interesting to also look at the 
association of two potential contributors to endocrine resistance, AP-2γ and FOXM1 in 
MCF-7 derived anti-oestrogen resistant cell lines (MLET1, MLET2, MLET5, MCF-7/TAM
R
-
4 and MCF-7/TAM
R
-7).  
 
The work in chapter 4 was focused on Forkhead transcription factors (FOXM1, FOXA1 and 
FOXC2) and ERα in MCF-7 cells and MCF-7 derived anti-oestrogen resistant cell lines 
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(MLET1, MLET2, MLET5, MCF-7/TAM
R
-4 and MCF-7/TAM
R
-7). The presence of 
FOXM1, FOXA1 FOXC2 and ERα as individuals or through association with each other in 
endocrine sensitive and resistant cell lines suggests the importance of Forkhead transcription 
factors and ERα in breast cancer development and progression. However, more studies on 
FOXC2 should be conducted to further elucidate its contribution to breast cancer aetiology. 
Two complementary approaches should be carried out to investigate the role of FOXC2 in 
endocrine sensitive and resistance. FOXC2 should be silenced in cell lines expressing high 
levels of FOXC2 to determine whether it has an effect on FOXM1, FOXA1 and ERα 
expressions. On the other hand, FOXC2 should be over-expressed in cell lines that either 
express FOXC2 at a very low level or do not express FOXC2 to determine whether an 
increase in FOXC2 expression could activate or repress FOXM1, FOXA1 and ERα 
expressions. By identifying the exact role of Forkhead transcription factors and their 
interaction with ERα in breast cancer sensitive and resistant cells, newer approach could be 
executed to combat the resistance to endocrine therapy.   
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